|Felipe Albrecht, PhD||Roche|
Bioinformatics and Computer Scientist, Pharma Research and Early Development (pRED)
Felipe Albrecht has a Bachelor, Masters, and PhD degree in Computer Science, but his projects were always related to molecular biology. During his PhD he was involved with Computational Epigenetics, working in word-wide projects. After his PhD he joined Roche in Germany. Where he first worked in the Mass Spectrometry department in the Large Molecule Research and Development, developing laboratory automation and data handling solutions. Currently, he is working in the Computational Engineering and Data Science department, where he is working with NGS data and providing bioinformatics solutions for the Large Molecules Discovery department. Felipe has extensive experience in software development as a developer to architect and project leader. He has experience in different programming languages, from C++ to Python, passing through TypeScript. Also, in different environments, such as Linux and Mac OS, and had developed tools using distributed computing. Currently, he is focusing on developing tools for support biological and pharmaceutical tasks using cloud computing.
|Brandon Allgood, PhD||Integral|
Brandon Allgood, PhD, is the VP, Head of Technology and Innovation at Integral Health. Prior to this Brandon was the CTO and cofounder at Numerate, Inc, an AI driven drug discovery company, which was acquired by Integral Health in September of 2019. At Numerate Brandon lead research and development of Numerate’s AI platform. He also led the data science group, was the primary technical lead on both internal and collaborative drug discovery programs and was responsible for the technology vision at Numerate. Prior to becoming CTO at Numerate Brandon also served as Director of Computational Science at Numerate and as a Research Scientist at Pharmix. He received a BS in Physics from the University of Washington, Seattle, and a PhD in Computational Physics from the University of California, Santa Cruz. Brandon has authored scientific publications in astrophysics, solid-state physics, and computational chemistry and biology and has 18 years of experience in AI, mathematical modeling, and large-scale cloud and distributed computing. He advises a number of venture capital firms and start-up companies, is a cofounder of the Alliance for AI in Healthcare, a member of the Forbes Technology Council and a University of California, Santa Cruz Foundation Trustee.
|Mohammed AlQuraishi, PhD||Harvard Medical School|
Systems Biology Fellow
I am an Independent Fellow in Systems Pharmacology at Harvard Medical School. Prior to joining Harvard, I completed my PhD in Genetics from Stanford University in the labs of Harley McAdams and Lucy Shapiro. Prior to that still, I worked at Wolfram Research developing computational biology functionality for Mathematica, and founded several startups in the software and mobile space. My research interests lie at the intersection of structural and systems biology.
|Rachana Ananthakrishnan||Globus, University of Chicago|
Rachana Ananthakrishnan is a Product Manager at the Computation Institute in the University of Chicago, and has a Staff Appointment at Argonne National Laboratory. Rachana works for the Globus project, designing and building secure data management solutions for researchers across domains, and help shape the services and offerings of the team. She has worked on security and data management solutions on various projects including Earth System Grid, Biomedical Informatics Research Network (BIRN) and XSEDE. Prior to this, she worked on the Globus Toolkit engineering team, leading the efforts in web services and security technologies. Rachana received her MS in Computer Science at Indiana University, Bloomington.
|Chris Anderson||Clinical OMICs|
No bio available
|Gustavo Arango, PhD||AstraZeneca|
Senior Data Scientist – Oncology Bioinformatics
Gustavo Arango is a PhD in computer science, Masters and Undergrad in Electrical Engineering who has been working in diverse areas through his scientific career, including: digital signal processing, web development, machine learning, bioinformatics, natural language processing and deep learning. Currently, he is working in the oncology bioinformatics team at AstraZeneca where he is applying deep neural networks to learn patterns from genomics data. Prior, he received his PhD (2019) from the department of Computer Science at Virginia Tech, where he developed bioinformatics tools to process metagenomics data. Particularly, by using machine learning and deep learning to leverage accurate predictions of antibiotic resistance genes from second and third generation sequencing technologies.
|Abel Archundia||Bayer Pharma AG|
Global Head, IT & Digital Transformation
Abel joined Bayer July 2017, as head of IT and Digital Transformation for Bayer Pharma, and member of Bayer Group IT Board. Before joining Bayer, Abel was Global CIO, Sandoz Division (Generics, 2012-) as well as head of IT for Novartis Technical Operations (~85 plants) looking after manufacturing, supply chain and quality (2015-) and member of the Novartis IT and Business Services Board. Past positions include Cemex (CIO Europe-Asia from Madrid), Dell (General Manager, Mexico, and Supply Chain, Latin America) and Boston Consulting Group (Principal, Monterrey and Dallas offices). He holds a degree in electronics engineering from Tec de Monterrey, Mexico, and an MBA and Public Management degree from Stanford Graduate School of Business. Abel is married and has two children, young men who keep him on his toes. He enjoys sports like competitive rowing and swimming, loves the outdoors and is a lousy golfer.
CEO and Co-Founder
Ardy Arianpour is CEO & Co-Founder of Seqster, an award-winning SaaS healthcare platform that enables organizations to drive efficient healthcare via comprehensive medical records (EHR), individual genomic profiles (DNA), and personal health device data. For the first time, users create their own matched, longitudinal health data profile across all of their US-based healthcare data sources through person-centric interoperability. Ardy is a visionary health tech executive and serial entrepreneur in biotech and digital health. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and SVP of Ambry Genetics that sold to Konica for $1B in 2017. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. 2019 Recipient of Top 40 Healthcare Transformer and SDBJ 40 under 40.
|Timothy Aungst, PharmD||MCPHS University|
Associate Professor, Pharmacy Practice
Timothy Aungst, PharmD is an Associate Professor of Pharmacy Practice at MCPHS University, Worcester, MA. He is passionate about the role of digital health in patient care. His first pursuits in the field was writing for multiple companies on mHealth and Digital Health, with a focus on mobile apps for patient utilization and recommendation for prescribing my providers. Since then, he has conducted research on digital health technologies in the pharmacy space and published in multiple peer review journals and spoken at multiple venues on the topic. He hopes to inspire the pharmacy profession to further integrate digital health into patient care and raise awareness on the future possibilities posed in the coming decades.
|J Christian Baber, PhD||Takeda|
Head, Scientific Informatics
No bio available
|Rebecca Baker, PhD||National Institutes of Health|
Director, HEAL (Helping to End Addiction Long-term) Initiative, Office of the Director
Rebecca G. Baker, PhD, is the director of the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, in the Office of the Director, NIH. Dr. Baker leads coordination of NIH HEAL Initiative programmatic activities between the Office of the Director and relevant Institutes and Centers (ICs). She manages the Office of the NIH HEAL Initiative, including NIH HEAL Initiative staff, and oversees management of NIH HEAL Initiative governance committees. Dr. Baker helped develop the NIH HEAL Initiative, working closely with NIH and IC leadership. She also provides expert advice to and represents the NIH Director on initiative-related activities, including interagency efforts in pain and opioid research and policy. Prior to holding this position, Dr. Baker was special assistant to the NIH Director and the Principal Deputy Director working directly with NIH leadership to analyze complex biomedical research policy issues and assist in the development of new science and policy initiatives. Before that, she worked in the NIH Office of Science, Outreach, and Policy, where she worked on legislative, communications, and policy issues. Dr. Baker also worked in the NIH Office of Science Policy, where she contributed to the development and implementation of the NIH Genomic Data Sharing Policy. Previously, she worked as a postdoctoral scientist using next-generation DNA sequencing to identify novel disease-causing genes in patients with rare immunological diseases. She earned her PhD from the University of Pennsylvania and her bachelor's degree from Cornell University.
|Dorothee Bartels, PhD||X The Moonshot Factory|
Clinical and Real World Data Strategy Lead
Dorothee B. Bartels is Clinical and Real World Data Strategy Lead at X, Alphabet. She used to be Corporate Head of Global Epidemiology at Boehringer Ingelheim (BI) for 10 years and for nearly two years Chief Digital Science Officer in the digital incubator of BI. She holds a Professorship of Epidemiology and Public Health at Hannover Medical School and is Adjunct Professor at McGill University, where she lectures in the course of Advanced Pharmacoepidemiology. Her research is focused on secondary data use and data linkages, on innovative real world data analysis approaches, new strategies for faster drug developments and approvals, and digital epidemiology, in particular combining AI/ML and traditional epidemiological methods
|L Michelle Bennett, PhD||National Cancer Institute|
Director, Center for Research Strategy
Dr. Bennett directs NCI’s Center for Research Strategy, a science-based office that since 2015 collaboratively develops recommendations for addressing scientific opportunities, monitors the direction and application of scientific knowledge and resources, and identifies research funding gaps. Prior to taking on this role, she served as the deputy scientific director of the Division of Intramural Research at the National Heart, Lung, and Blood Institute and before that was deputy director at NCI’s Center for Cancer Research. Dr. Bennett earned her PhD in oncology from the University of Wisconsin–Madison studying genetic susceptibility to cancer and, as a postdoctoral fellow at the National Institute of Environmental Health Sciences, performed some of the earliest work on BRCA1 and BRCA2 including the characterization and localization of BRCA1 to the long arm of Chromosome 17. Dr. Bennett has extensive practical experience in promoting collaboration and team-based approaches by bringing together research scientists with diverse backgrounds and expertise to solve complex scientific problems. She has supported efforts to increase diversity in the biomedical workforce, played a leadership role in launching and building the NIH Stadtman Tenure Track Investigator program, and developed a trans-NIH web presence for the NIH Intramural program. Dr. Bennett is the recipient of many awards, including NIH and Institute Director’s Awards, the NCI Women’s Scientist Advisors Achievement Award, and the NCI Exceptional Mentor Award.
|Dennis Bergau, PhD||AbbVie|
Senior Research Pharmacologist & Operations Lead Cardiac Safety
Dr. Dennis M. Bergau received a Bachelor of Science in Biology from Northeastern University in Boston, which included a work study program at the Harvard School of Public Health in the Bernard Lown Cardiovascular Laboratories. Before, during, and after his Physiology Master of Arts Degree work at Boston University, he spent 10 years working in the departments of Cardiology and Cardiovascular Surgery at Children's Hospital-Boston doing pre-clinical and clinical research. Upon completion of his MA efforts, he was a programmer for 10 years at Hewitt Associates, a Human Resources consulting firm. Dr. Bergau joined Abbott Laboratories in 2007 where he grew an internally-developed Machine Learning system into a functional area, making Abbott, part of which later became Abbvie, one of only two large pharma companies in the industry to have their own internal ECG core lab with worldwide ECG processing capabilities. His efforts have contributed to 8 successful regulatory approvals. While working full time at Abbott/Abbvie, he earned a PhD in Biomedical Engineering with a focus in Bioinformatics from the University of Illinois at Chicago. Dr. Bergau has recently collaborated with Medical Affairs and Key Opinion Leaders to develop and present international seminar content for the clinical applicability of AI in the treatment of Rheumatoid Arthritis, he is currently developing a framework to evaluate drug efficacy on apoptotic pathways in oncology, and contributing to the expansion of internal automated ECG analysis capabilities to identify novel electrophysiological biomarkers.
Director, Translational Research Business Technologies
Jay Bergeron is Director, Digital Client Partner for Early Clinic Development and Integrative Biology at Pfizer. He served as the Scientific Coordinator of IMI-eTRIKS, a $30M Public Private Partnership for building open source translation research information management systems.
|Devipsita Bhattacharya, PhD||SUNY Albany|
Assistant Professor, Information Security & Digital Forensics
Devi Bhattacharya is an Assistant Professor in the Department of Information Security and Digital Forensics at the University at Albany, SUNY. She holds a doctorate in Management Information Systems (MIS) from the University of Arizona. Her research interests include online news propagation, large scale network analysis, and information security and performance analysis of distributed computing systems.
|Govinda Bhisetti, PhD||Biogen|
Principal Investigator and Head of Computational Chemistry
Govinda Bhisetti is a Principal Investigator and Head of Computational Chemistry department at Biogen. His joined Biogen in 2014. Govinda got his Ph. D. from Indian Institute of Science, Bangalore in 1986. He moved to Scripps Research Institute, La Jolla, CA in 1987 to do to post-doctoral research. His work at Scripps involved use of Cray XMP supercomputer to simulate protein-ligand interactions and design novel inhibitors. From there, he went to work at Vertex Pharmaceuticals Inc. in 1990 and worked in the Computational Sciences department for 22+ years where he led molecular modeling and drug design efforts on several drug discovery projects. His research at Vertex led to the discovery of three FDA approved drugs: two AIDS drugs, Agenerase (amprenavir) and Lexiva (fosamprenavir), and one Hepatitis C drug, Incivek (Telaprevir). He is a co-inventor of these drugs and named inventor on 26 patents. He published 72 research papers including review articles and book chapters. His current activities include application of state of the art computational methods in the discovery of novel drugs for neurodegenerative and neuroinflammatory diseases.
|Brian Bissett||IEEE USA|
Jeff founded Bioinformatics.org in 1998 and co-founded Scilico, LLC in 2015. He received his MSc in Chemistry & Biochemistry from Boston College in 1999. At Bioinformatics.org, Jeff created its career-advancement resources, including those for training and employment. By working together with Martin to create Scilancer, Jeff is continuing to help people pursue careers in the scientific and technological fields.
|Celeste Blackman||Green Zone Culture Grp|
Celeste Blackman, co-founder of the Green Zone Culture Group and the Radical Collaboration for Women Program.
Celeste has over 20 years of experience building positive, high-trust work environments that energize and engage the human spirit. She helps leaders, managers and teams reduce their defensive behaviors so they can work better together! The results: greater levels of accountability, higher productivity, more enthusiastic engagement, deeper levels of trust and respect, and more creative and collaborative problem solving.
Celeste has worked with a wide range of clients including: NASA, the Natioanl Cancer Institute, Goodyear, Business Consultants of Japan, Siemens, The Department of Defense, and Vanderlande Industries.
|Vivien Bonazzi, PhD||Deloitte Consulting LLP|
Chief Biomedical Data Scientist, Managing Director
Vivien Bonazzi, PhD, recently joined its government and public services practice as both a managing director and its chief biomedical data scientist for Deloitte Consulting LLP. In this position, Bonazzi will focus on helping federal agencies utilize data science methods, technologies and cyberinfrastructures to better understand and utilize biomedical data. Previously, Bonazzi was a senior advisor in the Office of the Director at National Institutes of Health (NIH) as well as co-founder and leader of the NIH Data Commons. In her role, she focused on creating connections across all NIH institutes, other government agencies, nonprofit, and commercial organizations in the U.S. and internationally to create new ways to share, access, analyze, find and provide attribution to biomedical data and tools regardless of geographical location, size, or complexity of Prior to NIH, Bonazzi held several roles in the private and nonprofit sector, including Bonazzi holds a Bachelor of Science degree from the University of Canberra, Australia, and a master's degree and doctorate in biomedicine and computational biology from the University of Melbourne, Australia.
|Edward Bowen, PhD||GlaxoSmithKline|
Vice President, AI & Machine Learning
Ed Bowen is Vice President, AI & Machine Learning in R&D at GlaxoSmithKline (GSK). He leads a team of machine learning engineers using AI as a technology multiplier for GSK’s R&D strategy, enabling the discovery and development of transformational treatments for patients. His team delivers models and solutions across a wide range of medicines discovery problems including Target validation, enhanced clinical trial design, medicines scale-up, medicines portfolio optimization, protein engineering, and molecular design. Ed participate or leads a number of industry initiatives, notably establishing a TransCelerate workstream sharing Placebo and Standard of Care clinical data across 17 companies for use in enhanced clinical trial design. The goal of the workstream is to gain a greater understanding of the placebo effect and apply practical applications of the data to accelerate medicines testing while reducing patient burden. Ed holds an MA in Biology from Brown University, an MBA from Rensselaer Polytechnic Institute, a Master of Science in Electrical Engineering from the University of Rhode Island and a Bachelor of Science in Electrical Engineering from the US Coast Guard Academy. He is currently completing a PhD in Molecular Biology at the University of Miami.
|Dani Bradnan, MS||Lux Research|
Research Associate, Digital Health and Wellness
Dani is a Digital Health and Wellness Research Associate at Lux Research with deep expertise in digital therapeutics, digital biomarkers, and FemTech. Prior to her time at Lux, Dani worked as an Environmental Group Manager for a water treatment company, surveying and developing treatment plans for waterborne pathogen outbreaks in healthcare facilities across the United States. Dani graduated with a Masters Degree in biology from the University of Louisiana at Lafayette.
|Daniel Butnaru, PhD||Roche Diagnostics GmbH|
No bio available
|Lawrence Callahan, PhD||FDA|
Chemist, Office of Health Informatics, Global Substance Registration System/Office of Health Informatics, Office of Chief Scientist
Larry is a chemist at the FDA responsible for the development of ISO data standards and the Global Substance Registration System (GSRS). He collaborates with the NIH and other leading researchers in industry and academia on standards and ontologies for regulatory submissions.
|Tanya Cashorali||TCB Analytics LLC|
CEO and Founder
Tanya Cashorali is the founding partner of TCB Analytics, a Boston-based data consultancy. Prior to launching TCB Analytics, she worked as a data scientist at Biogen. Tanya started her career in bioinformatics and has applied her experience to other data-rich verticals such as telecom, finance, and sports. She brings over 10 years of experience using R in data scientist roles as well as managing and training data analysts, and she’s helped grow a handful of Boston startups.
CEO and Co-Founder
Corey is the CEO and co-founder of Bodyport, a medical device company developing a novel remote cardiac monitoring system aimed at reducing hospitalizations through the early detection of changes in patient status. Prior to founding Bodyport, Corey was the co-founder and CEO at Atreo Medical, where he led the design of a proprietary sensor for measuring cardiopulmonary resuscitation (CPR) quality to help improve survival outcomes from cardiac arrest. He led the company from its inception through its acquisition to Medtronic. Following the acquisition, Corey joined Medtronic and led technology transfer and sensor development for the TrueCPR product. Corey's experience spans biomedical instrumentation and algorithms engineering. He holds 25 issued and pending patents, and his inventions have been featured in Popular Science and Time Magazine’s ‘Inventions of the Year’. He is originally from Ottawa, Canada and holds a degree in biomedical and electrical engineering from McMaster University.
|Vijay Challa||Takeda Pharmaceuticals Inc|
Associate Director, Digital Clinical Platform and Technologies, Data Sciences Institute, R&D
No bio available
|Bing-Yuan Chen, PhD||Genentech Inc|
Lead Informatics Analyst
No bio available
|Xiang Chen, PhD||St Jude Children's Research Hospital|
Assistant Member, Computational Biology
Dr. Xiang Chen is an assistant member in the Dept. of Computational Biology at St. Jude Children’s Research Hospital in Memphis, TN, USA. He is also the member of AACR and ASCB. He received his BS degree in Biochemistry from Fudan University in Shanghai, China, MS degree in Biochemistry in Biochemistry from National University of Singapore in Singapore and PhD degree in Biological Sciences and MS degree in Computational and Statistical Learning from Carnegie Mellon University in Pittsburgh, PA, USA. He has completed his postdoctoral training in Biostatistics at Yale University School of Medicine in New Haven, CT, USA. Dr. Chen’s main research interest is in development and application of novel machine learning based analytical methods for high-throughput, multi-platform omics data in delineating genetic alterations and epigenetic deregulations in pediatric solid tumors, especially those leading to tumor relapse and metastasis. He is also interested in developing experimental models to understand functional roles in tumorigenesis for candidate cancer driver genes emerged after critical evaluation of omics data. Dr. Chen has over 20 years of in-depth research experience in molecular/cellular biology, computer science and statistical genetics and has made major contributions to understanding the genetic and epigenetic landscape of pediatric cancers in both computational method development and data analysis. He has published more than 70 research papers in top-tier, high-impact biomedical journals, including Nature, Nature Methods, Nature Genetics, Cancer Cell, Cell Report, Genome Biology, Nucleic Acids Research and Nature Communications. He has also authored several invited review articles and a book chapter. He is a regular reviewer for scientific journals including Nature, Nature Methods, Nature Communication, Genome Biology, Nucleic Acids Research, Plos Computational Biology, Plos Genetics, Bioinformatics and others.
|Sean Cheng, PhD||Philips Ventures|
Sean is currently an Investment Manager at Philips Ventures, a portfolio of promising health tech companies including Babyscripts, Xealth, Mytonomy, as well as a fund-of-funds to fulfill the Philips Healthtech strategy. He is interested in early-stage investment opportunities in digital health, medical devices and therapeutics.
Previously, Sean held positions at the Boston Consulting Group, the US FDA, and NASA. Sean also serves on the Board of Directors of The Professional Center for Child Development, Board of Advisors at the Johns Hopkins University, and the Advisory Council of the World Economic Forum's Global Shapers Community. Sean holds a PhD in Engineering from the University of Cambridge in England, where he developed expertise in medical device design and optimization algorithms.
|Jer-Ming Chia, PhD||Microsoft|
Principal Program Manager
Dr. Jer-Ming Chia is a Program Manager in the Azure HPC team at Microsoft. Trained as a computational biologist, Jer-Ming holds a PhD in Human Genetics, and works on delivering high performance computing solutions to customers with complex workloads.
Vice President, R&D Operations and Oncology IT
Strategic, visionary leader with an established track record of building and leading multidisciplinary, global Informatics and IS/IT teams, driving change and simplification and delivering value through innovation. Over 20 years experience in the biotechnology and pharmaceutical industry working in both Discovery and Development leading projects, managing complex portfolios, driving change programs, identifying opportunities for strategic initiatives, and translating scientific and medical questions into innovative solutions. Areas of particular strength include: strategy development and implementation, translational medicine, biomedical and health informatics, evidence-based decision makings, scientific and competitive intelligence, and "Big Data" exploitation.
|Michael Conway||National Institute of Environmental Health Sciences (NIEHS)|
Data Systems Architect/Engineer
No bio available
|Seth Cooper, PhD||Northeastern University|
Assistant Professor, Khoury College of Computer Sciences
Seth Cooper is an Assistant Professor in the College of Computer and Information Science and a member of the Playable Innovative Technologies Lab. Prior to joining Northeastern, Seth was the Creative Director of the Center for Game Science at the University of Washington. He previously worked in industry at Square Enix, Electronic Arts, and Pixar Animation Studios. A pioneer of the field of scientific discovery games, Seth’s PhD dissertation, “A Framework for Scientific Discovery through Video Games”, won the 2011 ACM Doctoral Dissertation Award. His work has shown that video game players are able to outperform purely computational methods for certain types of structural biochemistry problems, effectively codify their strategies, and integrate with the lab to help design real synthetic proteins. In addition to developing video games to solve problems and involve the public in science, he’s published research in character animation and crowd simulation.
ITS Digital Innovation Market Lead
Eduardo is the lead for Sanofi’s Digital Innovation. He’s got experience in two successful startups and organizations like Philips Medical and Intel healthcare. Eduardo is a graduate from MIT Sloan.
|Timothy Cutts, PhD||Wellcome Trust Sanger Institute|
Head, Scientific Computing
Tim is responsible for the provision of all the IT services which specifically deliver scientific data and computation. This includes: private and hybrid cloud services; high performance computing (HPC) clusters; high performance filesystems for data analysis; training in the use of HPC and cloud resources; data management systems for scientific data; research and development of IT technologies for solving tomorrow's scientific problems; and, IT support for core business IT systems, included databases, financial and HR systems.The changing focus of the Institute has led to us concentrating on a few areas:
• Scientific reproducibility. Creating IT and informatics systems which enable the portability of scientific analysis between collaborating institutions, and between on premise and other cloud environments, according to scientific need.
• IT Research and Development. Looking further down the road to identify technologies and approaches which could transform today's impossible scientific questions into something tractable and affordable.
• Pre-configured systems. To free the team's time to assist scientists with their computational challenges we are moving, where possible, to pre-configured hardware systems rather than building them by hand. An example area where we are following this approach is in Lustre parallel filesystems. This becomes as easier as these technologies gradually become more mature and mainstream.
• Flexible secure architecture. Science changes all the time, and the approaches to it change all the time. IT technology generally lasts 5 years, which means we must deploy solutions which have the maximum flexibility to adapt to unknown requirements years from now. We are actively promoting and using private cloud infrastructure with software-defined storage and networking to enable scientists to deploy experimental working environments rapidly and without adversely impacting their colleagues.
• Collaboration. We are actively involved in the Global Alliance for Genomics and Health, Health Data Research UK, the Pan-cancer project, and other projects building infrastructures for the sharing and collaborative analysis of large volumes of data.
During his previous role creating and leading the Infrastructure Management Team, he focused on a number of areas:
• Server virtualisation and consolidation. The previous strategy of buying traditional highly available server pairs for providing services was replaced with a virtualisation strategy, going from zero to more than 1000 virtual machines in the course of a couple of years. Virtualisation has now expanded from this established base towards use in computational and data sharing areas.
• Automation. Configuration management of our Linux and Windows estates to minimise the effort in administering thousands of machines.
In the Informatics Support Group, he was an enthusiastic early adopter of blade server technology, deploying our first blade cluster in 2002, squeezing a then-un-precedented 768 cores into just two 19" racks.
He also took part in our early work with parallel filesystems, deploying IBM GPFS for the storing of large shared datasets.
Incyte Genomics (formerly Hexagen)
Here I gained experience on being the customer of scientific IT services, and the skills and techniques needed to run large scale analysis efficiently on limited IT resources.
I developed and ran the company's SNP-calling pipeline, and visualised that data for the senior company scientists.
I was also involved in customer engagement, discussing data needs of customers, and made contributions to the perl framework used by the LifeSeq product to generate and deliver the data to customers.
PhD: Checkpoint Controls in the Latter Half of the Mammalian Cell Cycle
CRC DNA Repair Research Group
Dept of Zoology, University of Cambridge
My research was focused on the contrasting behaviour of human and rodent transformed cell lines with respect to their G2/M phase checkpoints following perturbation of their nucleotide pool levels during S-phase.
|Chris Dagdigian||BioTeam Inc|
Co-Founder and Senior Director, Infrastructure
Bioinformaticist-gone-bad Chris Dagdigian has spent much of the last 15 years designing, building, fixing and improving research-focused HPC and IT systems for use in demanding production computing environments. He occasionally is known to blog, tweet and speak about industry trends and best practices. Formerly of Blackstone Computing and Genetics Institute, Dagdigian specializes in research computing and infrastructure technology issues in the life sciences. A supporter of free software and open standards for life science research, he is a founding member of the Bioperl Project, co-founder of the Bioclusters mailing list and serves on the board of directors as Treasurer of the Open Bioinformatics Foundation.
Senior Vice President, Informatics and Data
Mark has a background in molecular genetics and bioinformatics and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Projects and eventually moved on to building Chemogenomics systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI) as one of the founding members and technical lead for the ChEMBL resource - the largest open-source SAR database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI.
|Kevin Davies, PhD|| |
Executive Editor, The CRISPR Journal; Founding Editor, Bio-IT World
Kevin has almost three decades’ experience in science publishing as an editor, journalist, author and publisher. He is the founding editor of Nature Genetics and Bio-IT World magazine and also served as Editor-in-Chief of Cell Press and publisher of Chemical & Engineering News. Kevin is the author of four popular science books including Cracking the Genome, The $1,000 Genome, and an updated version of DNA: The Story of the Genetic Revolution with James D. Watson and Andrew Berry. In 2017, Kevin won a Guggenheim Foundation fellowship in science writing. That same year, he joined Mary Ann Liebert Inc. to spearhead the launch of The CRISPR Journal and join the GEN editorial team. Kevin holds a degree in Biochemistry from Oxford University and a PhD in Human Genetics from St Mary’s Hospital Medical School, London. He carried out postdocs at MIT and Harvard Medical School before joining the editorial staff at Nature. He still clings to a British accent.
|Brandi Davis-Dusenbery, PhD||Seven Bridges Genomics Inc|
As CSO at Seven Bridges, Brandi oversees all aspects of scientific innovation with a focus on creating solutions that accelerate biomedical discovery. Brandi leads the development of collaborative data analysis ecosystems for the National Cancer Institute and National Heart Lung and Blood Institute where she works with stakeholders to shape novel mechanisms and global standards for data access, analytical reproducibility, and usability. Brandi holds a PhD in Biochemistry from Tufts Sackler School of Medicine.
|Guillermo del Angel, PhD||Alexion Pharmaceuticals|
Senior Director, Data Sciences, Genomics and Bioinformatics
Guillermo del Angel, PhD is currently Sr. Director for Data Science, Genomics and Bioinformatics at Alexion Pharmaceuticals in Boston, MA. Since joining Alexion in 2015 he has been leading research efforts focused on applying and developing different machine learning and data science approaches to improve rare disease target discovery, drug development, patient diagnostics and disease characterization. He previously held positions as a consultant at McKinsey & Co. in Mexico City and Boston, and as a computational biologist at the Broad Institute of Harvard and MIT in Cambridge, MA. A native of Mexico City, he originally trained as an electrical engineer and applied mathematician, earning a BS degree from ITESM in Mexico, a MS from Boston University and a PhD from Cornell University.
|Helena Deus, PhD||Elsevier Inc|
Technology Research Director
Dr. Helena Deus is a Technology Research Director for Elsevier Labs. She received her PhD in Bioinformatics from Universidade Nova de Lisboa, where she focused on linked data and semantic web applications for healthcare and life sciences with an emphasis on cancer research. Helena is a data scientist passionate about applying data integration and machine learning techniques to the generation of insights affecting clinical practice and biomedical discovery. Before she joined Elsevier in 2017, Helena's roles included directing a knowledge engineering and data science team at Foundation Medicine and leading projects and strategy for Health Care and Life Sciences at the Digital Enterprise Research Institute, National University of Ireland at Galway (DERI/NUIG). Helena has published over 30 peer reviewed papers. She was one of the winners of the Big Data Track in the 2013 Semantic Web Challenge and of the Linked Data Cup with her work on linking data from The Cancer Genome Atlas.
|John Dey||Fred Hutchinson Cancer Research Center|
Senior HPC Systems Engineer
No bio available
|Jiarui Ding||Broad Institute|
Jiarui Ding is a postdoctoral associate in the Aviv Regev lab at the Broad Institute of MIT and Harvard. Dr. Ding received a PhD in computer science from the University of British Columbia in 2016. His research focuses on developing statistical models and efficient algorithms to learn biologically interpretable latent structures in large-scale, high-dimensional single-cell genomics data, such as those from single-cell transcriptomics, single-cell epigenomics, and spatially resolved methods. He is interested in integrating these datasets generated by cutting-edge single-cell genomics technologies to provide a comprehensive view of biological systems, and understand how they change dynamically under disease perturbations (e.g., food allergy, cancer) and treatments.
|Ariel Dowling, PhD||Takeda Pharmaceuticals|
Director, Digital Strategy Lead, Data Sciences Institute
Ariel V. Dowling, PhD is a Director of Digital Strategy within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the strategy, assessment, and deployment of digital devices in clinical studies and related activities across the organization. She advises clinical teams on the selection of digital devices, conducts due diligence on vendors, develops digital sensor implementation protocols and risk mitigation strategies, and assists with data analysis plans for device data. Prior to joining Takeda, she was a Senior Clinical Data Scientist at Biogen Inc where she oversaw the analysis of data from wearable sensors deployed in drug development clinical trials for Parkinson’s Disease. Prior to Biogen, Ariel was the algorithm team lead at MC10 Inc, where she oversaw the development and implementation of algorithms across the full product line and managed all aspects of algorithm testing that lead to a successful FDA submission. She has also worked as a senior research scientist at BioSensics LLC, where she designed algorithms to analyze digital device data from Huntington’s disease patients, stroke patients, and wheelchair users. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and a BE in Mechanical Engineering from Dartmouth College.
|Dora Elguezabal||Thermo Fisher Scientific Inc|
|Jake Emerson||The Jackson Laboratory|
Computational Lead, Cube Initiative and Principal Scientific Software Engineer
My professional career started in the US Army Corps of Engineers. While stationed in Alaska, the Marshall Islands, the Republic of Korea and Iraq, I worked as a construction engineer, project manager, explosives and demolitions trainer, and logistics officer. After military service, I have been involved in both the worlds of startups and academia. I have led projects in a variety of fields including: hydrologic warning, field maintenance operations, crisis informatics, oceanographic event analysis, and software development. I have also been an assistant instructor in the Department of Spatial Information Science and Engineering at the University of Maine. I hold a BS in mechanical engineering from the U.S. Military Academy at West Point, and a MS in environmental engineering from the the Missouri University of Science and Technology.
|Phil Eschallier||RCH Solutions|
With more than 25 years experience as a managerial and technical computing professional, Phil currently leads RCH’s Managed Services capabilities and is responsible for all elements of the customer experience, including requirements and resources management, and services definitions and delivery. His professional background includes solutions architecting, scientific and high performance computing design and support, life sciences applications management, and software engineering from both management and technical perspectives.
|Kjiersten Fagnan, PhD||Lawrence Berkeley Natl Lab|
Chief Informatics Officer, Data Science and Informatics Leader, DOE Joint Genome Institute
In April 2016, Dr. Kjiersten Fagnan became the JGI’s Chief Informatics Officer. She responsible for developing and executing the strategic plan for computing and data analysis. Dr. Fagnan joined the JGI in 2012 after completing a petascale postdoctoral fellowship at the DOE National Energy Research Scientific Computing Center (NERSC) and the Computational Research Division at Berkeley Lab. In 2014 Fagnan became the JGI-NERSC Engagement Lead and focused on adapting JGI data-intensive workloads to run on supercomputing hardware. She is also the group lead for NERSC’s Data Science Engagement group and leads efforts to build collaborations between NERSC and other DOE facilities.
|Ian Fore, PhD||NIH NCI|
Senior Biomedical Informatics Program Manager, Center for Biomedical Informatics and Information Technology
Dr. Ian Fore is a Senior Biomedical Informatics Program Manager at the National Cancer Institute’s Center for Biomedical Informatics and Information Technology with a focus on data integration in both basic and clinical science. Current contributions are in managing NIH and NCI interests in data discovery and in establishing Commons for research data. Dr. Fore is an active participant in the Research Data Alliance and FORCE11. He previously led CBIIT’s programs in biorepository and pathology informatics. Previously Dr. Fore worked on drug discovery informatics at Wyeth Research in both the UK and USA, and at Johnson & Johnson Pharmaceutical R&D including developing global databases for research data. He was a product manager at Celera Genomics responsible for programmers interfaces. Prior to leaving the lab for an informatics career Ian gained his DPhil in Physiology at the University of Oxford and subsequently worked as a Research Pharmacologist.
|Xiaowu Gai, PhD||Children’s Hospital of Los Angeles|
Director, Bioinformatics; Associate Professor, Clinical Pathology, Pathology & Laboratory Medicine
I am a human geneticist and a bioinformatician. My primary research interest is in understanding human genetic variations and how they are related to human diseases, including constitutional disorders like mitochondrial diseases and pediatric cancers. I have served as the head of bioinformatics at four different biomedical institutions. Currently, I am an Associate Professor of Clinical Pathology at the Keck School of Medicine of USC, and also the Director of Bioinformatics for the Center for Personalized Medicine at the Children's Hospital Los Angeles. At the Center, we develop and implement a variety of genomics-based tests for both pediatric cancers and for constitutional disorders, including the clinical exome-sequencing test and in particular the OncoKids test for pediatric cancers that we developed in collaboration with Thermo Fisher Scientific. I am responsible for the informatics solutions for all of our tests, which is highly relevant to the proposed research. At the Center, we have been using ClinVar/ClinGen resources and following strictly AMP/ACMG guidelines. I currently serve as a Multi-PI for a NICHD-funded U24 grant, aiming to curate disease-gene and gene-variant pathogenicity assertions in relation to Leigh and Leigh-like syndromes. I have had extensive involvement in many large research projects, having served as PI, Co-PI, or Co-Investigator on a number of university-, hospital-, or NIH-funded grants.
|Jyotin Gambhir, MB, CISM||SecureFLO LLC|
Jyotin Gambhir (Founder/Consultant | SecureFLO, LLC| SECaaS – Security as a Service) GRC | SECaaS | DaaS | IDM | WAF | Security Architecture | DDOS | Compliance| Policy Development| | SaaS Introduction Mr. Gambhir has an extensive experience in Information Security, Risk, Privacy, and technology. He has worked with a wide array of clients in varying verticals for over eighteen (18) years. My most recent experience in the CISO role is building an IT Risk Management Program, focused on IT security for a large Healthcare organization network in the Northeast. Jyotin has experience in Financial Services, Retail, Research and Development, Biotechnology/Pharmaceutical, Healthcare, and the Government sectors. At Deloitte, he worked for six years in managing large projects at Fortune 100 companies. His teams deployed complex solutions for some of the largest financial services, state and federal government, and telecom industry clients. Jyotin has worked extensively with senior management and board of directors to develop strategies, vision, and direction for Information security programs. He has hands on experience started in security operations on mainframe environments, which encompassed the areas of privacy and security regulations, data protection, vulnerability management, operational security, and identity and access management. His current focus has on the data lifecycle within businesses and looking at each aspect of security from data creation to its destruction and disposal. Jyotin’ has developed frameworks to manage various aspects of the information security programs using NIST, ISO, HI-TRUST, CIS and other standards and models. This standards-based approach provides the ability to address multiple areas of compliance and regulations and provides for consistency. Prior to joining SecureFLO, LLC, Mr. Gambhir was with recognized consulting firms such as Deloitte, Tivoli/IBM, and BMC Software. During his current and past tenures, he has delivered successful initiatives across multiple industries such as Telecommunications, Energy, Healthcare/ Pharmaceuticals, Federal Government, Financial Services, Higher Education, Manufacturing, and Law Enforcement.
|Victoria Gamerman, PhD||Boehringer Ingelheim|
Head of US Health Informatics and Analytics
As the Head of Health Informatics and Analytics (HIA), Victoria leads a team of experts in cross-functional collaborations on various initiatives within the competitive environment to optimize BI’s ability to meet current and emerging needs for Real World Evidence to help meet patients’ needs. The HIA team at Boehringer Ingelheim is a global team uniquely positioned to leverage the rich information from Real World Data using advanced analytics for Big Data through close collaborations with internal/external partners to foster efficient patient-oriented clinical development programs. Prior to leading the HIA team, Victoria worked as both a project and trial statistician providing expert advice in designing and analyzing data from various sources using appropriate analytic and statistical techniques. She earned her PhD in Biostatistics and Master’s in Biostatistics from the University of Pennsylvania’s Perelman School of Medicine and a Master’s and Bachelor’s in Mathematics from Boston University. She currently also teaches at Columbia University.
Director, Data Analytics, Data Science Institute
Yan Ge is the Director of Data Analytics in the Data Sciences Institute at Takeda Pharmaceuticals. An industry veteran with over 20 years of experience in the Life Sciences and Healthcare, Yan has built up Analytics and Data Science capabilities at three different companies including Takeda. His focus in Takeda are research including discovery, translational and real-world plus applications of AI/ML to address R&D challenges. Before Takeda, Yan served in data analytics leadership roles in Ascensia Diabetes, Telcare, Deloitte Consulting, Medidata and IBM among others. Yan holds multiple graduate degrees in Statistics, Molecular Biosciences and MBA with his BSc in Applied Chemistry from Peking University, China.
|Nils Gehlenborg, PhD||Harvard Medical School|
Assistant Professor, Department of Biomedical Informatics
Nils Gehlenborg received his PhD from the University of Cambridge and was a predoctoral fellow at the European Bioinformatics Institute (EMBL-EBI). The goal of Gehlenborg’s research is to improve human health by developing computational techniques and interfaces that enable scientists and clinicians to efficiently interact with biomedical data. Tight integration of algorithmic approaches from biomedical informatics with advanced data visualization techniques is central to his efforts, as is close collaboration with clinicians and experimentalists. Currently, Gehlenborg is researching and developing novel tools to visualize heterogeneous data from large-scale cancer genomics studies such as The Cancer Genome Atlas, integrating visual and computational approaches to support sense-making in biology, and using software to support reproducible collaborative research in epigenomics and genomics. Gehlenborg is a co-founder and former general chair of BioVis, the Symposium on Biological Data Visualization, and co-founder of VIZBI, the annual workshop on Visualizing Biological Data. Occasionally, he contributes to the “Points of View” data visualization column in Nature Methods. Gehlenborg currently serves as the Director of the Master of Biomedical Informatics (MBI) program at Harvard Medical School.
|Laura Goetz, FACS, MD, MPH||City of Hope Comprehensive Cancer Center|
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Division of Clinical Cancer Genomics
The daughter of a doctor and a public health nurse, Laura H. Goetz, MD, MPH, knew early on she wanted to become a physician and help others. Along the way she became a decorated U.S. Army veteran, a talented cancer surgeon and a fierce believer in using every available tool – from public education campaigns to the latest genetic breakthroughs – to help prevent cancer.
Dr. Goetz holds a medical degree from University of Minnesota and a Masters in Public Health from University of California Berkeley. She is certified in cancer genetic risk assessment and most recently directed the Cancer Prevention and Early Detection program at TGen (Translational Genomics Institute), City of Hope’s genetic research affiliate. She is passionate about the new field of “precision prevention” which collects detailed data on cancer mechanisms, inherited risks and environmental factors to create a specialized prevention plan for each patient.
Dr. Goetz is a lieutenant colonel in the U.S. Army Reserve Medical Corps. She served in Operation Iraqi Freedom and earned the Army Commendation Medal and Combat Action Badge, both in 2011.
|David Gosalvez, PhD||PerkinElmer|
No bio available
|Robert Green, MD, MPH||Brigham & Women’s Hospital, Broad Institute, and Harvard Medical School|
Professor of Medicine (Genetics) and Director, G2P Research Program/Preventive Genomics Clinic
Robert C. Green, MD, MPH is Professor of Medicine (Genetics) at Harvard Medical School and a physician-scientist who directs the G2P Research Program at Brigham and Women’s Hospital and the Broad Institute. Dr. Green is internationally recognized for research and policy efforts accelerating the implementation of genomic/precision medicine.
Education and Training: Dr. Green graduated Amherst College and University of Virginia School of Medicine, with MPH in epidemiology from Emory University School of Public Health. His specialty training was at Harvard Medical School residencies and he is board certified in both neurology and medical genetics.
Research Achievements: Dr. Green led the first experimental trials disclosing common complex disease risk (REVEAL Study) and the first prospective studies of direct-to-consumer genetic testing services (PGen Study). He currently leads and co-leads the first NIH funded randomized trials of sequencing in adults (MedSeq Project), newborns (BabySeq Project), and active duty US military personnel (MilSeq Project). He created the concept of aggregate penetrance of genomic variants in prospective population cohorts and is demonstrating the feasibility of genomic sequencing in healthy newborns, paving the way for humans to gain lifelong medical benefits from genomics. With continuous funding from NIH for 26 years he has published more than 300 papers with an h index of 90. In 2014, he won the Coriell Prize for Scientific Achievement in Personalized Medicine, and in 2019 was named by BIS Research as one of the 25 most influential voices in precision medicine. Since joining the Harvard Medical School faculty in 2011, the G2P research team has been awarded research support of over $49 million.
Research Leadership: Dr. Green recently co-chaired the Steering Committee of both the Clinical Sequencing Exploratory Research program (18 NIH grants, over 300 investigators), and the Steering Committee of the Newborn Sequencing in Genomic Medicine and Public Health program (4 NIH grants, over 100 investigators) and is a co-investigator on the Boston site within the Electronic Medical Records and Genomics Network. He is Associate Director for Research of Partners HealthCare Personalized Medicine and is leading the development of protocols for return of genomic results for the All of Us Research Program of the United States Precision Medicine Initiative and the Google/Verily Project Baseline.
Policy Leadership: Dr. Green is accelerating the worldwide implementation of medical genomics. He was lead author on the influential recommendations for managing incidental findings in clinical sequencing from the American College of Medical Genetics and Genomics and contributing author on recommendations for managing incidental findings in research biobanks among participants and among family members of participants. He is a Board Member of the Council for Responsible Genetics and works within the Global Alliance for Genomics and Health and the All of Us Research Program on designing efforts to return research information, particularly genomic information, to research participants.
Clinical Care: Dr. Green directs the Preventive Genomics Clinic at Brigham Health, providing evidence-based genomic and multi-omics evaluation to early adopters seeking to anticipate and prevent future illness.
Entrepreneurship: Dr. Green co-founded Genome Medical, a telegenomics technology and services company providing genetics expertise to patients, providers, employers and healthcare systems.
Presentations & Media: Scientific plenary presentations include American College of Medical Genetics/Genomics, Cold Spring Harbor, AGBT, European Society for Human Genetics and BioData World. Presentations to business include Forbes Healthcare Summit, World Science Festival, Future of Genomic Medicine, Exponential Medicine, Festival of Genomics, Aspen Ideas Festival, SXSW, Asian Healthcare Leadership and JP Morgan. His work and commentary have been featured on PBS television/radio, NBC Nightly News, CBS Sunday Morning, Today Show, CNBC, the Doctors, New York Times, Wall Street Journal, Time Magazine, New Scientist, FastCompany, GenomeWeb, Gizmodo and Buzzfeed. Research findings from Genomes2People Research are highlighted in these podcasts, blog posts and videos.
Research Support: Dr. Green’s research is supported by grant funding from the National Institutes of Health, the Department of Defense, the Snite Foundation and the Franca Sozzani Fund for Preventive Genomics.
Disclosures: Dr. Green receives compensation for advising the following companies: AIA, Applied Therapeutics, Humanity, Verily; and is co-founder of Genome Medical, Inc, a technology and services company providing genetics expertise to patients, providers, employers and care systems.
|Nigel Greene, PhD||AstraZeneca Pharmaceuticals|
Director, Head, Data Science and Artificial Intelligence, Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences
Nigel Greene leads the Data Science and Artificial Intelligence department in Clinical Pharmacology and Safety Sciences at AstraZeneca and is interested in the application of artificial intelligence methods to understand of mechanisms of drug-induced toxicity and their translation to a clinical patient population. Previously Dr. Greene was a head of the Predictive Compound ADME and Safety group at AstraZeneca. Dr Greene also spent 14 years at Pfizer, Inc. where he started in Drug Safety R&D and later transitioned to the Compound Safety Prediction group in Medicinal Chemistry. In his early career, Dr. Greene worked for Lhasa Ltd. where he pioneered computational toxicology, and for Tripos, Inc.
Nigel’s other activities outside of AstraZeneca have included being the Chair of the Board of Trustees for Lhasa Ltd. and he has served on multiple National Research Council committees sponsored by the US Environmental Protection Agency, US Food and Drug Administration, and the National Institutes of Health.
Dr. Greene received his BSc and PhD from the University of Leeds in the UK.
|Susan Gregurick, PhD||National Institutes of Health|
Associate Director, Data Science (ADDS) and Director, Office of Data Science Strategy (ODSS)
Susan K. Gregurick, PhD, was appointed Associate Director for Data Science and Director of the Office of Data Science Strategy (ODSS) at the National Institutes of Health (NIH) on September 16, 2019. Under Dr. Gregurick’s leadership, the ODSS leads the implementation of the NIH Strategic Plan for Data Science through scientific, technical, and operational collaboration with the institutes, centers, and offices that comprise NIH. Dr. Gregurick was instrumental in the creation of the ODSS in 2018 and served as a senior advisor to the office until being named to her current position. Dr. Gregurick was previously the Division Director for Biophysics, Biomedical Technology, and Computational Biosciences at the National Institute of General Medical Sciences (NIGMS). Her mission in this role was to advance research in computational biology, biophysics and data sciences, mathematical and biostatistical methods, and biomedical technologies in support of the NIGMS mission to increase our understanding of life processes. In this role Dr. Gregurick led the institutes effort to reimagine the NIGMS technology programs including early stage, concept development, focused technology programs, development and dissemination centers, through National and Regional Resources to support state-of-the-art facilities, equipment, technologies, research tools, software, and service. Prior to joining the NIH in 2013, Dr. Gregurick was a program director in the Office of Biological and Environmental Research at the Department of Energy (DOE). In this role, she developed the information and data sharing policy for the agency’s Genomics Science Program and oversaw the development and implementation of the DOE Systems Biology Knowledgebase, a framework to integrate data, models, and simulations together for a better understanding of energy and environmental processes. Dr. Gregurick is an advisory council member for the DOE’s Office of Advanced Scientific Computing Research and a member of two National Science Foundation advisory committees – the Biological Sciences Advisory Committee and the Computer and Information Science and Engineering Committee. She has received several awards during her tenure at NIH, including two NIH Director’s Awards. Before beginning a career of government service, Dr. Gregurick was a professor of computational chemistry at the University of Maryland, Baltimore County. Her research interests included dynamics of large biological macromolecules, and her areas of expertise are computational biology, high performance computing, neutron scattering and bioinformatics. Dr. Gregurick received her undergraduate degree in chemistry and mathematics from the University of Michigan and her PhD in physical chemistry from the University of Maryland. She completed a Lady Davis postdoctoral fellowship at Hebrew University in Israel and a Sloan postdoctoral fellowship at the University of Maryland’s Center for Advanced Research in Biotechnology, now the Institute for Bioscience & Biotechnology Research, in Shady Grove, Md.
|Robert Grossman, PhD||University of Chicago|
Frederick H. Rawson Distinguished Service Professor in Medicine and Computer Science; The Jim and Karen Frank Director, Center for Translational Data Science
Robert L. Grossman, PhD, is the Frederick H. Rawson Distinguished Service Professor in Medicine and Computer Science and the Jim and Karen Frank Director of the Center for Translational Data Science at the University of Chicago. He joined the faculty in 2010 and has served as the chief research informatics officer of the Biological Sciences Division since 2011. He is the principal investigator for the National Cancer Institute Genomic Data Commons (GDC), a platform for the cancer research community that manages, analyzes, integrates, and shares large-scale genomic datasets in support of precision medicine. The GDC was used by more than 100,000 researchers in the past year. He has also built data commons to support research in other areas, including cardiology, infectious diseases, neuroscience, and the environment. His research interests include data science, machine learning, and deep learning. He is a member of the Frederick National Laboratory Advisory Committee for the National Cancer Institute and of the Science Advisory Board for the National Oceanic and Atmospheric Administration. He earned his PhD in applied mathematics at Princeton University and an AB in mathematics from Harvard University.
|Rishi Gupta||AbbVie Inc|
Principal Research Scientist, Data Science and Informatics
Rishi R. Gupta is currently a Principal Research Scientist at Abbvie, Inc. at Lake County, Chicago. He leads the Cheminformatics and Competitive Intelligence groups. At AbbVie, he has developed a web based infrastructure to expose suite of Cheminformatics tools called AIDEAS. He has developed and deployed machine learning models for a variety of bioassay data including ADMET endpoints. In his extended role within Competitive Intelligence (CI), Rishi is developing web based visual-analytic frameworks for exposing genomics data, clinical Trials data and a variety of other CI related landscapes e.g. KOLs. Prior to AbbVie, Rishi was at Pfizer Global Research and Development as a Computational Chemist where he had broad set of responsibilities ranging from developing ADMET in-silico models, novel scoring methods such as confidence metrics for in-silico models. He also supported the Anti-Bacterial research organization. Rishi earned his PhD from University of Connecticut where he developed systems engineering approaches for genetic pathway analysis and also developed computational methods for application in drug discovery.
|Shweta Gupta||Cambridge Consultants Inc|
Director, Global Medical Technology
No bio available
|Karl Gutwin, PhD||BioTeam Inc|
Senior Scientific Consultant
Karl joined BioTeam in 2017 with a background in cloud, high-performance computing and scientific computing applications. He focuses on complex system architecture, implementation and support, particularly for informatics workflows in data science and the life sciences. Karl received his PhD from the Massachusetts Institute of Technology, studying methods for predicting protein-protein interaction structure. He then joined Biogen, where he worked as a scientific application support specialist and HPC administrator, before joining Biogen’s Data Sciences group as a data engineer. There, Karl was part of a team that brought in high-speed cloud and collaboration connectivity with Internet2 and AWS, and built a dynamically reconfigurable computing environment for data science exploration. Having moved to Biogen’s Scientific Computing group, Karl worked to build a cloud HPC capable of performing multi-sample joint exome calling on tens of thousands of samples in a week. He also led a team of developers building end-to-end workflow automation for NGS pipelines.
|Farhan Hameed, MD||Pfizer Digital|
VP, Global Real World Data – Strategy, Analytics & Insights (GRWD-SAI), Analytics, Informatics & Business IntelIigence (AIBI)
Farhan "CJ" Hameed is a biomedical informatician and real-world data strategist with diverse experience in healthcare, spanning academia, patient care, clinical research and informatics for over 18 years. In his current role at Pfizer, he focuses on development and harvesting strategic alliances for end-to-end utilization of real-world data (RWD) in drug development to generate regulatory grade real-world evidence (RWE). In his earlier work at Pfizer, CJ led Informatics initiative at the Quantitative Medicine and Neuroscience Research Units and steered the development and implementation of semantically driven interoperable drug discovery analytics platforms and knowledge management systems for multiple therapeutic areas. In Digital Medicine group and Pfizer Innovative Research (PfIRe) Lab, his team led the development of analytics-based reporting systems leveraging AI & Machine Learning by incorporating ontologies, clinical and wearables data standards for the real world and clinical trial studies. Prior to joining Pfizer, CJ led several clinical informatics projects, built multi-specialty evidence-based knowledgebase systems in partnership with several international academic institutes and publicly funded organizations and steered development of international drug databases, and clinical decision support systems (CDSS). He also held several academic positions in the past – an Associate Professor at the College of Pharmacy at Chicago State University and Midwestern University and, currently, teaches at Northeastern University, Boston Health Informatics graduate program. CJ holds a master's degree in health informatics from Northeastern University and a medical degree from Dow University of Health Sciences. He is a HIMSS fellow and recently attained American Medical Informatics Association fellowship status.
|Ian Harrow, PhD||Pistoia Alliance Inc|
Consultant Project Manager and Manager, FAIR Implementation and Ontologies Mapping Project
Ian Harrow manages the FAIR Implementation and Ontologies Mapping Projects for the Pistoia Alliance. He is an indepenedent consultant providing expert project management and data analytics for real world problems. His consultancy is also a partner for the BioExcel Centre of Excellence for Biomolecular Research. He has over 30 years experience working in and for the Pharmaceutical and Life Science industry and obtained a PhD from the University of Cambridge, UK.
|Samiul Hasan, PhD||GlaxoSmithKline|
Scientific Analytics and Visualization Director, Data and Computational Sciences
Samiul Hasan is a director within the Scientific Analytics Visualization team at GSK. Samiul’s passion is in using computational techniques including semantic technologies to enhance scientific decision making and increase the chances of getting better treatments to patients more quickly. Prior to his current role, Samiul was with GSK’s Computational Biology group for over 10 years. In that time, he implemented several analysis pipelines for critical GSK drug projects and was instrumental in developing widely used technical infrastructure including OpenTargets. Before his GSK career, Samiul completed a 2-year Bioinformatics postdoctoral fellowship at the Novartis Institute of Tropical Diseases in Singapore where he applied machine learning approaches for prioritizing drug targets in pathogens. This came after his PhD in Bioinformatics at the Wellcome Trust Sanger Institute/University of Cambridge where he was applying similar methods for predicting regulatory regions in human DNA.
|Neda Hassanpour, PhD||Takeda Pharmaceuticals Inc|
No bio available
|Qais Hatim, PhD||U.S. Food and Drug Administration|
Successful statistician/operation research analyst and industrial engineering professional with experience in univariate/multivariate statistical techniques, categorical data analysis, analysis of variance/covariance (ANOVA/ANCOVA) and multivariate analysis of variance/covariance (MANOVA/MANCOVA), performing testing procedures utilizing reliability analysis tools, censored data analysis, using stochastics processes in modeling reliability problems, structured and unstructured data mining, design of experiment, process control, simultaneous statistical inference, Bayesian modeling, sustainable and agile manufacturing dynamic system modeling and simulation, large-scale optimization, development of analytical tools and scalable computational schemes for optimization and equilibrium problems, real-time big data analytics for manufacturing system, and supply chain management. Recognized as a self-starter and quick learner with providing exceptional, innovative, and efficient solutions to business problems through a profound knowledge of the underlying physics and mathematics as well as computational tools, written and verbal communication skills, and excellent work ethic.
|Richard Head, MS||Washington University School of Medicine|
Professor, Genetics and Pathology & Immunology; Director, Genomics, McDonnell Genome Institute Genetics; Genome Technology Access Center at the McDonnell Genome Institute (GTAC@MGI)
As the Director of Genomics at the McDonnell Genome Institute (GTAC@MGI), I bring 28 years of experience in medical research, with more than 22 years in the development and application of high-throughput genomic technologies (next generation sequencing, microarray, and high-throughput PCR). In addition to large-scale data generation, I also maintain considerable expertise in the analysis and interpretation of the same, particularly with regards to drug discovery, clinical research and patient care. In my years within the pharmaceutical industry and academia, I led numerous successful efforts in the discovery of novel drug targets, identification of drug mode of action, biomarkers for patient stratification, elucidating the translatability of pre-clinical models, and ascertaining the causes for drug failures. My current primary research interests focus on the development of novel interpretive analytical methods for multi-omics data and their use in the areas of inflammation & immunology, oncology, and cardiovascular & metabolic diseases.
|Allison Heath, PhD||Children’s Hospital of Philadelphia|
Director, Data Technology and Innovation, Center for Data-Driven Discovery in Biomedicine (D3b)
Allison Heath is the Director of Data Technology and Innovation responsible for providing technical and collaborative leadership to build platforms for data-driven discovery that span across both research and operational efforts. She provides supervision of the data products and platforms team which performs basic and applied research in data intensive computing, bioinformatics, cloud computing, and related areas. Since joining CHOP in 2017, Allison and her team have been working on solving big data challenges in the unique context of pediatric diseases, including leading the development of the Kids First Data Resource Center (DRC).
|Michael Heinke||Bayer Business Svcs GmbH|
Director, Global Pharma Strategy
Michael is driving digital transformation and new digital business models in close collaboration with the functional representatives at Bayer Pharma. This includes identification and prioritization of new digital business opportunities as well as the build-up of critical capabilities as well as fostering the needed cultural changes and talent management. Before he joined Bayer he worked in Strategy Consulting focusing on the digitalization of Healthcare and the concomitant convergence of industry. He helped various global leading Pharma clients to leapfrog existing business models and digital solution by creating truly customer centric offerings and enhancing the analytics driven utilization of various internal and external data. Prior to that he worked at the pharmaceutical industry in multiple Commercial and Medical line management positions at global and country level.
Georges founded Databiology in 2013 to provide a biomedical information management and orchestration platform for the life sciences and healthcare sectors. Under his leadership and product vision, Databiology has grown into an established global company with offices in the US, UK, Hong Kong and Mexico with a leading platform solution for globally distributed biomedical data, applications and infrastructure.
|Peter Henstock, PhD||Pfizer Inc|
AI & Machine Learning Technical Lead
Peter Henstock is working to transform Pfizer using AI and Machine Learning. He is the Machine Learning and Technical Lead in Pfizer’s Digital group based in Massachusetts. He holds a PhD in Artificial Intelligence from Purdue University and Master’s degrees in Biology, Software Engineering, Statistics, Applied Linguistics, and Image Processing. Before joining Pfizer, Peter worked at MIT Lincoln Laboratory in image processing and computational linguistics. He also teaches graduate level Machine Learning & Data Mining and Software Engineering at Harvard University.
|Spencer Hey, PhD||Harvard Medical School|
Faculty and Co-director of Research Ethics
Dr. Hey is a faculty member and Co-Director of Research Ethics at the Harvard Center for Bioethics. He received his PhD in philosophy from the University of Western Ontario and BA (Honors) in philosophy from the University of Illinois at Chicago. He previously held a postdoctoral fellowship in the Biomedical Ethics Unit at McGill University and a visiting scholarship at Oxford University.His research interests lie at the intersection of biomedical ethics and philosophy of science—with a focus on clinical trials and ethical challenges across the drug research and development enterprise. His published work has appeared in scientific, medical, bioethics, and philosophical venues, including Science, Neurology, The BMJ, PLoS Medicine, STAT News, Journal of Medical Ethics, Hastings Center Report, Perspectives in Biology and Medicine, and Philosophy of Science.
Sara Nygaard has 9 years of experience in applying biological interaction (PPI) network analyses to enhance performance in pharma projects within target and biomarker discovery, treatment response and drug repositioning. Now, she is dedicated to bringing some of these tools into the hands of pharma R&D scientists, through Intomics’ inBio platform that allows for advanced data analyses and biological interpretation in the context of high confidence PPI-maps and supports collaboration between bioinformaticians and biological scientists.
|Xinjun Hou, PhD||Pfizer|
Director, Computational Chemistry
No bio available
|Michael Huang||Thermo Fisher Scientific|
Product Manager, Digital Science
No bio available
|Yu-Shan Huang||Daopin Incorporation|
No bio available
|Hongmei Huang, PhD||Roche Genentech|
Senior Director, Head of Development Sciences Informatics, Development Sciences
Hongmei Huang is the Head of Informatics for Development Sciences at Genentech, a member of the Roche Group. In this role, she is responsible for the strategic leadership around data management, informatics systems and analytics platforms for translational research and development functions including Biomarker Development and Safety Assessment. She also serves on the leadership team for the Roche wide effort to make data FAIR across R&D. Hongmei is an accomplished Informatics leader with 25 years of experience in the Pharmaceutical/Biotech Industry. She started her career as a Research Investigator and transitioned into Informatics over the course of her career, with leadership roles in various companies including Novartis and Johnson & Johnson.
|Bonnie Hurwitz, PhD||Univ of Arizona|
Assistant Professor, Biosystems Engineering
Dr. Bonnie Hurwitz is an Assistant Professor of Agricultural and Biosystems Engineering at the University of Arizona and Bio5 Research Institute Fellow. She has worked as a computational biologist for nearly two decades on interdisciplinary projects in both industry and academia. Her research on the earth and human microbiome incorporates large-scale –omics datasets, high-throughput computing, and big data analytics to answer questions in systems biology. In particular, Dr. Hurwitz is interested how viruses re-engineer host metabolism and the implications on host-driven processes. Dr. Hurwitz is well-cited for her work in computational biology in diverse areas from plant genomics to viral metagenomics with over 2600 citations.
|Daniel Huston||Bristol-Myers Squibb Co|
Lead IT Business partner, Translational Bioinformatics IT for Translational Medicine
No bio available
|Michael Iarrobino||Copyright Clearance Center|
Director, Product Management
Mike Iarrobino is Director of Product Management for CCC'saward-winning content and rights workflow suite, RightFind®. He has previously managed marketing technology and content discovery products at FreshAddress, Inc., and HCPro, Inc. He speaks at webinars and conferences on the topics of content discovery and data management.
|Yuval Itan, PhD||Icahn School of Medicine at Mount Sinai|
Assistant Professor, Department of Genetics and Genomic Sciences; Members, Charles Bronfman Institue for Personalized Medicine
Dr. Yuval Itan is an Assistant Professor in the Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology and a core member of The Charles Bronfman Institute for Personalized Medicine, at the Icahn School of Medicine at Mount Sinai in New York City. The main focus of the Itan lab is investigating human disease genomics for enhancing precision medicine, by developing new computational methods to detect disease-causing mutations and genes in next generation sequencing data of patients, and by performing cases-controls studies of patient cohorts to identify new genetic etiologies of human diseases. The Itan lab applies and combines diverse approaches across computer science and biology, including machine learning, natural language processing, bioinformatics, statistical genomics, modelings and simulations, and population genetics. Education: BSc, Bar-Ilan University; PhD, University College London;
Postdoc, The Rockefeller University.
|Alexander Ivliev, PhD||Clarivate Analytics|
Alex Ivliev is Director of Bioinformatics at Clarivate Analytics, the leading provider of life science informatics and services. Alex holds a PhD in bioinformatics. For the past 8 years, Alex has been working in service and consulting roles, helping pharmaceutical companies transform data into insights and build predictive models to support drug discovery research.
Associate Director, Global Data Science
Adam is the Lead Data Scientist at Biogen, where he works on optimizing commercial outcomes through marketing, patient outreach and field force infrastructure utilizing data science and predictive analytics. Biogen is a leader in the treatment and research of neurological diseases for 40 years. Prior to being commercial lead, Adam was part of their Digital Health team where he worked on next generation application of wearable and neurological tests. Holding a PhD in genomics, he also teaches management skills for data science and big data initiatives at Boston College.
|Ewa Jermakowicz||Roche Pharma|
IT Business Partner for PD Scientific Decision Support
Ewa Jermakowicz is an IT Business Partner in the Scientific Decision Support Network at Roche, supporting Biometrics and wider Product Development activities. Her current focus is on processes and tools supporting FAIRification of data coming from clinical trials. She's an IT Lead implementing a Platform allowing to pool clinical data with molecular, genomics and digital biomarkers for diverse therapeutic areas to fully capitalize Roche scientific data in support of Reverse Translation. Prior to this role she has been the Informatics Project Manager leading number of global multimillion projects in the clinical and real world data space. She has been with the company for 10 years with previous experience in a global financial institution.
|Bino John, PhD||AstraZeneca Pharmaceuticals|
Associate Director, Data Science - Clinical Pharmacology & Safety Sciences
Bino John, PhD, currently leads a variety of Artificial Intelligence (AI) Initiatives at AstraZeneca (AZ). As an Associate Director at AZ, he is leveraging Deep learning and other advanced AI approaches to accelerate Drug development. Before joining AZ in 2018, Bino led a variety of computational biology initiatives and teams at Dow and then Dow-DuPont. In those roles, his efforts included enabling machine learning/AI and integrative big-data informatics capabilities for genomics research for the Agricultural Sector. He earned an Integrated Master’s degree in Chemistry from the Indian Institute of Technology (Mumbai) in 2000 and subsequently received his PhD from The Rockefeller University in Biomedical Sciences in 2003. His thesis research in computational structural biology with Dr. Andrej Sali was followed by postdoctoral studies in computational genomics with Dr. Chris Sander at the Memorial Sloan-Kettering Cancer Centre. In 2005, Bino joined the University of Pittsburgh as a faculty, where he focused on using high-throughput methods for cancer biomarker discovery, resulting in the discovery of novel molecules and molecular pathways.
|Graham Jones, PhD||Novartis Horsham Research Ctr|
Director, Innovation, Technical Research and Development
Following his PhD at Imperial College London, Graham was a NATO fellow at Harvard University where he worked with Nobel Laureate E. J. Corey. His independent academic career spanned 25 years and generated >$100 million external funding and 160 peer reviewed publications in the fields of drug discovery, drug delivery, process technology, regulatory science and medical devices. He held a number of leadership roles in the academy including pro-vice chancellor, vice provost and institute director, most recently Professor of Medicine and Director of Translational Research at the Tufts Clinical and Translational Science Institute (CTSI) in Boston MA. In 2018 Graham was recruited by Novartis as Director of Innovation. Graham has been a regular consultant to the pharmaceutical and biotechnology industry and was an advisor to the FDA in the development of the biosimilars approval pathway. He has also been instrumental in establishing and advising a large number of technology-based startup companies who have subsequently raised >$4B in venture funding. Graham sits on several advisory and editorial boards and has been the recipient of numerous awards for scientific and technology development. He was awarded the DSc in 2006 for contributions to medicinal chemistry.
|Jaidepp Joshi||Stelus Technologies|
Staff Solutions Engineer, Engineering
IT professional with over 20+ years of experience developing IT solutions. Solving unique data storage related challenges for life science organizations, in the areas of genomics, computational biology, and protein structure prediction. Primary focus on High Performance Storage with technologies such as HPC, Next Generation Sequencing, and High Speed Microscopy.
|Sanjay Joshi||Dell EMC|
Industry CTO, Healthcare
Sanjay Joshi is the chief technology officer for healthcare and life sciences in the emerging technologies division of Dell EMC. Based in Seattle, Sanjay's 28-plus year career has spanned the entire gamut of life sciences and healthcare from clinical and biotechnology research to healthcare informatics to medical devices. His current focus is a systems view of genomics, proteomics and healthcare for infrastructures and informatics.
|Natalija Jovanovic, PhD||Sanofi|
Chief Digital Officer
Natalija Jovanovic is the Chief Digital Officer at Sanofi Pasteur, the vaccines division of Sanofi. She has extensive experience in delivering digital solutions at AIG, the global insurer, and as VP of Innovation at Brown Brothers Harriman, a global commercial bank. Previously, Natalija was at McKinsey, the strategy consulting firm, and holds a PhD in electrical engineering from MIT.
Chief Data Officer
Milind Kamkolkar is the CDO of Cellarity. Milind is leading Cellarity’s diverse AI and Digital organization, which implements machine learning science on a digital biology landscape to explore new clinical hypotheses that can alter cell behaviors. Milind joined Cellarity from Sanofi where he was the first enterprise Chief Data Officer in the pharmaceutical industry. Milind’s focus was transforming Sanofi from a data-generation organization into a data-driven organization, to empower the lives of patients and enrich the value Sanofi delivered to customers. The approach was drawn from his tenure at Novartis where he was the Global Head of Data Science and AI in Digital Medicines. Milind is a featured speaker (TEDx), Business Transformation Top 150 Leader and thought leader in digital health, AI and big data. Milind has served as a board advisor and mentor to numerous startups, founders and VC firms focused on entering the life science space through digital, data or AI. He has served as an Honorary Lecturer for Physician Entrepreneurship at BartsX, Faculty at Exponential Medicine and a Former Special Advisor to the UN Global Compact Sustainable Development Goals program.
|Gurpreet Kanwar, MBA, PMP||NAV CANADA|
Senior Manager, Project Delivery Service
Gurpreet has been working as Project manager for more than 14 years with experience of 21 years in IT technical project planning and implementation industry. He helped establishing the PMO at his company and has managed many complex projects globally. Gurpreet works closely with customers and portfolio managers to help them resolve specific issues and problems regarding the projects. Gurpreet has MBA Degree from Edinburgh Business School.
Senior Software Engineer National Center for Advancing Translational Science
Danny Katzel has been a Senior Software Engineer at NIH’s National Center for Advancing Translational Sciences (NCATS) through RanchoBiosciences for the past 4 years. While at NCATS, Mr. Katzel has worked on the Global Substance Registration System, G-SRS, which provides a common identifier for all of the substances used in medicinal products, utilizing a consistent definition of substances globally, including active substances under clinical investigation. Previously, Mr. Katzel worked at The Institute for Genomic Research (TIGR) which later became the J. Craig Venter Institute (JCVI). During the 10 years he worked there, Danny was the lead Software Engineer for the Viral Genomics Group where he wrote the key components of most of the pipelines that have been used to sequence, assemble, analyze, annotate, and publish over 20,000 viral genomes to Genbank.
Principal Scientist, Translational Sciences
Erik Koenig has been a strategic leader in genomic sciences and computational biology focused on translational biomarker development including PD, resistance, safety and predictive patient selection ranging from protein homeostatis, targeted, ADC and immuno-oncology programs. Currently at Takeda, Erik is provide leadership for cross-functional strategic initiatives, like STORK, and plays a key role in fostering collaborations with functional and scientific leaders to innovate and operationalize transformative translational strategies aligned for patient benefit.
|Ivan Krstic, PhD||Elsevier Inc|
Director, Chemistry Solutions
Ivan Krstic, Director of Chemistry Solutions, Elsevier and his team is responsible for development of Reaxys, leading chemistry information solution for early drug discovery and development that:provides high quality reaction data and (predictive) retrosynthesis;provides the most comprehensive manually extracted medicinal chemistry data from patents and journals;enables integration of published data with in-house reaction, reagent and inventory data.
Ivan holds PhD in chemistry from Goethe University Germany.
|Hande Kucuk McGinty, PhD||Collaborative Drug Discovery|
Hande is a research scientist at CDD. She has been working with the BioAssay Express development team. Her most recent research focuses on bio-ontologies and their applications for artificial intelligence and machine learning.
Global Director - Emerging Technologies
No bio available
|Amir Lahav, ScD||Karyopharm Therapeutics, Inc.|
Digital Medicine and Innovation Lead; Digital Healthcare Intelligence, Mitsubishi Tanabe Pharma
Amir is a clinical neuroscientist specialized in digital medicine and digital health strategy. As a former Digital Health and Clinical Innovation Lead at Pfizer, Amir has developed a strategic vision focused on patient-centered outcomes empowered by real-world data to enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Drawing on his experience in the healthcare sectors, healthtech startups, and the drug development cycle, Amir brings an entrepreneurial zeal to the clinical world through innovation thinking and digital solutions from proof of concepts to scale-up solutions. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. Prior to pharma, Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health, where he had the pleasure of mentoring (and learning from) the talented students in his lab.
|Lee Lancashire, PhD||Cohen Veterans Bioscience|
Chief Information Officer
Lee Lancashire, PhD has over 15 years of experience in machine learning and statistics. His PhD was focused on the development of artificial neural network-based methodologies where he was involved in many of the first applications of neural nets to high dimensional datasets in bioinformatics. Prior to joining Cohen Veterans Bioscience, Lee spent over five years within the IP & Science business of Thomson Reuters where he established and led the machine learning and statistical data analysis team. Here he held global responsibility for managing and delivering analytical projects, serving the majority of the top 10 pharmaceutical companies, as well as government, academic and non-profit organizations. These projects focused on utilizing advanced machine learning approaches in the molecular profiling of disease for biomarker discovery, patient stratification and drug target identification. Lee completed his post-doctoral research in Biostatistics and Bioinformatics at the Paterson Institute for Cancer Research, a Cancer Research UK core facility. He has also worked as a bioinformatics project lead in personalized medicine and diagnostics companies CompanDX and Almac Diagnostics. He has published in over 30 key industry journals and holds several patents around the use of neural networks in the biomedical domain. In his free time Lee devotes time volunteering as a trustee for the Ichthyosis Support Group, a charity that supports individuals and families affected by a group of rare skin disorders.
ML/AI Lead, R&D Informatics, Small Molecule Discovery Informatics
No bio available
|Frederick Lee||Amazon Web Svcs|
Business Development - Life Sciences
Dr. Lee provides physician leadership in business development for an AWS New Initiative group focused on facilitating the data exchange in a regulatory compliant, ethically sound, economically sustainable, and secure cloud-native fashion. Fred's personal passion is accelerating the digitally-driven transformation of healthcare to a predictive, preventive, personalized, and participatory state.
|Sebastien Lefebvre||Alexion Pharmaceuticals Inc|
Senior Director, Data Sciences, Genomics and Bioinformatics
20 years of experience leading and building data and analytics capabilities in BioPharma. Currently at Alexion building data sciences capabilities and delivering insights in rare diseases working with BD and Commercial functions. In the prior role built the cloud-based Data Analytics & Decision Support environment for external collaboration. Past roles include Head of Global Data Office at Biogen and Head of Global R&D Information Architecture practice at AstraZeneca. Holds a MSc in Computational Chemistry and a MSc in Computer Sciences from Universitée de Montréal.
|Alexander Lex, PhD||University of Utah|
I am an Assistant Professor of Computer Science at the Scientific Computing and Imaging Institute and the School of Computing at the University of Utah. Together with Miriah Meyer, I run the Visualization Design Lab where we develop visualization methods and systems to help solve today’s scientific problems. Before joining the University of Utah, I was a lecturer and post-doctoral visualization researcher at Harvard University. I received my PhD, master’s, and undergraduate degrees from Graz University of Technology. In 2011 I was a visiting researcher at Harvard Medical School. I am the recipient of an NSF CAREER award and multiple best paper awards or honorable mentions at IEEE VIS, ACM CHI, and other conferences. I also received a best dissertation award from my alma mater. I co-founded Datavisyn, a startup company developing visual analytics solutions for the pharmaceutical industry, and the Caleydo project, an open source visualization framework for biomolecular data.
|Benjamin Li||Boehringer Ingelheim|
Global Head of ITRDM Biological Sample Production & Management, Information Technology
Zhenbin (Benjamin) Li is global head of IT RDM Biological Sample Production and Management. He is responsible for global IT needs related to biotherapeutics discovery and structure research in human pharma and animal health R&D. Benjamin holds a PhD degree from University of Georgia, and MS and BS from Nanjing University (China).
|Bin Li, PhD||Takeda Pharmaceutics|
Director, Computational Biology
Dr. Bin Li leads a translational bioinformatics team at Takeda’s global computational biology organization. His team provides computational supports on both forward and reverse translational research, on multiple therapeutic areas including oncology, GI, neuroscience, and rare diseases. They develop methods, build ML/AI predictive models, and do data-driven exploratory analyses for biomarker and patient stratification needs. His team is also responsible on method evaluation and pipeline building for various NGS platforms, including WES, RNA-seq, scRNA-seq, microbiome, and targeted panels.
|Michael Liebman, PhD||IPQ Analytics LLC|
No bio available
Senior Manager, Pfizer Digital
Yuan Lin is the Biologics Business Solution Lead in Pfizer Digital. He manages, develops, and supports Pfizer Biologics R&D informatics platforms. He is an experienced software architect/developer, business analyst, and bioinformatician. Before joining Pfizer in 2017, Yuan was a Senior Principle Business Analyst and Lead Software Engineer at Novartis, focusing on the in-house E2E biologics screening platform and leading the support of a global biologics registration platform. He led the implementation of an NGS data workflow system at GeneDX and built a comparative Genome Browser and Sequence Analysis platform that enabled the sequencing and analyzing of the first individual human genome at J Craig Venter Institute.
|Debbie Lin, PhD, MPP, MSc Eng||Boehringer Ingelheim Venture Fund USA, Inc.|
Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare. She joined Boehringer Ingelheim Pharmaceuticals in 2008. Within Boehringer Ingelheim Pharma, she worked across various regions and divisions. She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West Coast. She also led the US organization’s social entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka. In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Director of Corporate Development. There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation. She led multi-country teams to set up the company’s first stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal. Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton Administration. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA. Debbie is a native Californian, she loves sunshine, being around nature and the ocean, yoga and dogs.
|Millie Liu||First Star Ventures|
Founder, Managing Partner
Millie Liu has focused her career on helping entrepreneurs with deep technology turn their ideas into great businesses with global reach.
She was previously at APT, an enterprise data analytics startup acquired by Mastercard for $600 million where she helped Fortune 50 clients such as Walmart and P&G make better strategic decisions leveraging data. She was also the co-founder of an MIT startup working on unsupervised event detection, which later pivoted and became Infervision, an AI precision healthcare platform backed by Sequoia China. Millie is on the advisory board of MIT CSAIL (Computer Science and Artificial Intelligence Lab). She holds a Master of Finance degree from MIT and B. in Mathematics from the University of Toronto.
|Ray Liu||Takeda Pharmaceuticals|
Senior Director, Advanced Analytics and Statistical Consultation
No bio available
|Sean Liu, PhD||Takeda California Inc|
Global Head, Scientific Assets & Decision Support, Scientific Informatics
Based in San Diego, Sean Liu is leading the Scientific Assets and Decision Support group within Takeda R&D IT. His remit includes developing entity registration solutions for all modalities, assay data foundation to enable single source of truth for all assay data associated with the assets and data integration, visualization and predictive analytics to support data-driven decision making.
Director Market Access RWE Partnerships,
No bio available
|Alan Louie, PhD||IDC Health Insights|
Alan is responsible for directing the IDC Health Insights Life Sciences Practice. Dr. Louie manages a group of analysts who provide research-based advisory and consulting services for life sciences companies, technology vendors, and IT service providers across the life sciences value chain. Within the practice, Dr. Louie leads IDC Health Insights' Life Science R&D Strategy and Technology Research service with coverage of ongoing innovation and best practices in life science R&D and a further emphasis on technology and innovation in clinical development, analytics, translational research, and precision medicine. Dr. Louie brings more than 32 years of technology, product and strategy development from across the life science industry. Previously, Dr. Louie led applied biotechnology programs as Senior Manager at Arthur D. Little, Inc. In this role, he managed laboratory-based technology development programs, as well as provided content expertise to life science and healthcare strategy projects. Over his career, Dr. Louie was responsible for the development and commercialization of more than 30 products for a variety of industries, including many first-in-class product offerings.
|Nick Lynch, PhD||Curlew Research|
Founder and CTO
Nick has over 20 years’ experience in Data science & Informatics in various start-ups and biopharma. Interested in making data more accessible for better. Established Curlew Research in 2014 working with Pharma/biotech and Life Science informatics/data science companies.
|Avi Ma'ayan, PhD||Icahn School of Medicine at Mount Sinai|
Professor, Department of Pharmacological Sciences; Director, Mount Sinai Center for Bioinformatics
The research in the Ma'ayan Lab involves applying computational methods to study the complexity of regulatory networks in mammalian cells. We develop algorithms and software to study how regulatory networks control cellular processes such as differentiation, dedifferentiation, apoptosis, and proliferation. Our main focus is in developing methods that link changes in gene expression to transcriptional regulators and cell signaling pathways. To achieve this, we develop web-based bioinformatics software tools and databases that enable biologists to perform enrichment and network analyses to find new knowledge about single genes, gene sets, and drugs. Using these tools, we work closely with experimentalists on projects that utilize high-throughput profiling to understand cell regulation at the global scale. So far, we published over 160 peer-reviewed articles where several of them in top-tier journals. Over the past 12 years, about 100 trainees, including postdoctoral fellows, graduate and medical students, undergraduates, and high school students contributed to the laboratory work. The Ma’ayan Lab members participate in educational and outreach activities including delivering two MOOCs on the Coursera platform, a summer undergraduate research program, and two in-class graduate courses.
|Finlay MacLean||Elsevier Inc|
Finlay MacLean completed a Masters of Engineering in Biomedical Engineering at the University of Nottingham. He is currently working as a data scientist at Elsevier, primarily involved in drug repurposing, disease investigation and retrosynthesis prediction. He is passionate about aiding understanding of rare diseases through the use of novel computational methods.
|Thomas Madden, PhD||NCBI/NLM/NIH|
No bio available
|Ravi Madduri|| |
Scientist, Data Science and Learning, Argonne National Laboratory; Senior Scientist, University of Chicago Consortium for Advanced Science and Engineering (UChicago CASE)
No bio available
|Lara Mangravite, PhD||Sage Bionetworks|
Lara Mangravite, PhD, is President of Sage Bionetworks. This organization is focused on the development and implementation of practices for large-scale collaborative biomedical research. Our work is centered on new approaches to scientific process that use open systems to enable community-based research regarding complex biomedical problems. Previously, Dr. Mangravite served as Director of the Systems Biology research group at Sage Bionetworks where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite obtained a BS in Physics from the Pennsylvania State University and a PhD in Pharmaceutical Chemistry from the University of California, San Francisco. She completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children’s Hospital Oakland Research Institute.
|Sylvia Marecki, PhD||EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany|
Design Analyst, Operational Design Center (ODC), Global Clinical Operations
Sylvia Marecki joined the Operational Design Center within Global Clinical Operations at EMD Serono in 2019 as a strategic thought partner driving efficiency and innovation in study planning and execution. Prior to joining EMD Serono, Sylvia led development and commercialization of data-driven analytic products and services at Citeline/Informa, Decision Resources Group, and TriNetX, empowering informed decision-making across clinical and commercial functions at all stages of the product lifecycle. She received her Doctorate in Pathology and Immunology from Boston University School of Medicine.
Scientific Solutions Lead, Engineering
Adam Marko is an IT and Life Sciences professional with over 15 years of experience meeting the analytics and infrastructure needs of researchers. He has supported scientists in the agricultural, pharmaceutical, and diagnostic spaces. At Igneous, he helps HPC customers meet their data visibility, backup, and archive needs.
|Nicola Marlin||Pharma Intelligence|
Head of AI in R&D Information Research, Senior Principal Data Scientist
Brian joined AbbVie in October of 2018 as the head of the newly formed RAIDERS team within Research & Development’s Information Research division, focused on accelerating, scaling, and amplifying the work of AbbVie’s R&D community using Artificial Intelligence technologies like machine learning, deep learning, and cognitive computing. Brian came to AbbVie after spending five years in technology consulting across many industries, and over a decade of additional experience before that working in trading and financial markets technology. During his consulting time, Brian architected the United States’ Common Securitization Platform and was a founding member of Publicis.Sapient’s AI practice. While his primary focus is AI technologies, his interests are much broader, and he has presented at multiple conferences on topics including optical networking, quantum computing, blockchain, cognitive architecture, and other emerging technology concepts that are all part of digital transformation. Brian holds a BS degree in Computer and Cognitive Science from Alma College and a MS in Computer Science from the University of Chicago. He is actively involved with technology incubator programs at Mundelein and Lake Forest High Schools, the Creative Destruction Lab at the University of Toronto’s Rotman School, and is a member of the Education Committee for District 115’s Board of Education.
|Mark McCreary||Genentech Inc|
Biomarker Data Management and Curation Lead (DevSci Informatics)
No bio available
|Tyler McQuade, PhD||Medicines for All Institute|
Professor of Chemical and Life Sciences Engineering, Virginia Commonwealth University; CTO
A surfer-turned-scientist, Dr. McQuade studied organic chemistry at UC Irvine, UW Madison and MIT. He learned the principles of chemical engineering during his 14 years in academics in the U.S., Switzerland, and Germany, and as a Program Manager, Deputy Director and Acting Director of the Defense Science Office at the Defense Advanced Research Projects Agency (DARPA). Currently, McQuade is a Professor of Chemical and Life Science Engineering, the Chief Technical Officer of Medicines for All and the PI of the MPrint-OKN. MPrint-OKN seeks contribute the STEM segment of the future open knowledge network – a vision that is part semantic web, part AI/Data Science and part internet 2.0.
|Luis Mendez||Bristol Myers Squibb Co|
Senior Research Scientist, Immunoscience Drug Discovery Group
Luis A. Mendez is a Senior Research Scientist within the Immunoscience Drug Discovery group at Bristol-Myers Squibb (BMS). Luis received his BA in Biology and BS in Exercise Science from Rutgers University and his MS in Biotechnology with a Concentration in Biotech Enterprise from Johns Hopkins University. Luis has over 15 year’s industry experience.
|Christopher Meyer, PhD||Univ Of Chicago|
Scientific Support Analyst, Center for Translational Data Science (CTDS)
No bio available
|Annastasiah Mhaka, PhD||Alliance for Artificial Intelligence in Healthcare|
Co-Founder & President
Dr. Mhaka is an experienced lifesciences executive, investment professional, and biotech entrepreneur with a passion for global health. Leveraging expertise in biomedical discovery, technology development, healthcare delivery, and fundraising she creates transformative healthcare advances impactful on a global scale. Utilizing her experience in cross-disciplinary and multi-stakeholder approaches, Dr. Mhaka has co-founded the Alliance for Artificial Intelligence in (AAIH), a global organization dedicated to resolving the myriad challenges facing the growing field of AI and Machine Learning based life sciences and healthcare solutions. In addition to her proven track record of over 50 cross-industry deals in both the private and public sector, Dr. Mhaka has co-founded four companies, and generated over $200 million in deliverables within the drug development and nanotechnology sectors. Dr. Mhaka received her PhD in Cellular and Molecular Medicine from Johns Hopkins Medicine where she developed a clinical phase oncology drug and attained her Bachelor of Science in Chemistry [Highest Honors, Summa Cum Laude] from the University of Pittsburgh.
|Mark Michalski, MD||Mass General Hospital and Brigham and Women’s Hospital|
Executive Director, Center for Clinical Data Science
Dr. Michalski currently serves as the Executive Director of the Massachusetts General Hospital & Brigham & Women’s Hospital Center for Clinical Data Science (CCDS) where he oversees a staff of approximately 40, including data scientists, software engineers, data engineers, researchers, trainees, and clinical experts. Regarded as an emerging leader at the center of the application AI in clinical medicine, the CCDS was formulated as an early-stage technology company focused on developing and translating AI technology for clinical applications, operations, and population health. Previous to this role, Dr. Michalski helped create and grow two medical device/diagnostic companies: Butterfly Network (a novel ultrasound-based technology which has recently launched their first product) and Hyperfine Research (in stealth mode), where he served in leadership roles at both organizations (as president and chief medical officer). He has conducted research focused on machine learning, medical 3-D printing, molecular diagnostics and other areas, and has published in JAMA, PLOS, and PNAS. Previous to these roles, Dr. Michalski worked with technology, healthcare, and strategy groups at Genentech and Google in various roles. He completed his clinical training in diagnostic radiology as a Holman fellow at Yale, and was a med scholars researcher at Stanford.
|Pietro Michelucci, PhD||Human Computation Institute|
Dr. Michelucci directs the Human Computation institute. He received a joint-PhD from Indiana University in Cognitive Science and Mathematical Psychology and has been a science advisor to federal research agencies since 2006. He has supported the emergence of Human Computation as a formal discipline through a Springer handbook, an open-access scholarly journal, speaking engagements and workshops, interagency initiatives in Social Computing, and Citizen Science working groups. In 2014, he led the Human Computation Roadmap Summit, a CRA-funded 3-day workshop at the Wilson Center with input from the White House OSTP, toward a national initiative in Human Computation. As an Organismic Computing pioneer, he is interested in developing new methods for augmenting group efficacy, and developing related applications that will benefit humanity. He currently leads the EyesOnALZ project, which uses crowd-based methods to accelerate Alzheimer's research through an online game called Stall Catchers. Dr. Michelucci has been a visiting professor at Cornell University since 2016.
|Kenna Mills Shaw, PhD||MD Anderson Cancer Center|
Executive Director, Institute for Personalized Cancer Therapy
Dr. Shaw is executive director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute). She joined The University of Texas MD Anderson Cancer Center in 2013, bringing an extensive background in science leadership and education. Dr. Shaw is responsible for daily operations at the Khalifa Institute and its work to improve molecular characterization of tumors and apply that knowledge to clinical trials and advanced patient care. She also is operations director for MD Anderson’s Cancer Genomics Laboratory and administrative director of the Precision Oncology Decision Support System. Prior to joining MD Anderson, Dr. Shaw spent four years with The Cancer Genome Atlas (TCGA), a flagship project of the National Cancer Institute focused on accelerating understanding of the molecular basis of cancer. She was scientific projects manager for
a year, during which she served as the lead technical and public communications officer. In 2010 she was promoted to director and provided oversight and leadership to the TCGA’s complex research program with more than 300 funded components. Dr. Shaw earned undergraduate degrees in Spanish and Biology at the College of William and Mary, and completed her doctoral degree in cell and developmental biology at Harvard University. Dr. Shaw is executive director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute). She joined The University of Texas MD Anderson Cancer Center in 2013, bringing an extensive background in science leadership and education. Dr. Shaw is responsible for daily operations at the Khalifa Institute and its work to improve molecular characterization of tumors and apply that knowledge to clinical trials and advanced patient care. She also is operations director for MD Anderson’s Cancer Genomics Laboratory and administrative director of the Precision Oncology Decision Support System. Prior to joining MD Anderson, Dr. Shaw spent four years with The Cancer Genome Atlas (TCGA), a flagship project of the National Cancer Institute focused on accelerating understanding of the molecular basis of cancer. She was scientific projects manager for a year, during which she served as the lead technical and public communications officer. In 2010 she was promoted to director and provided oversight and leadership to the TCGA’s complex research program with more than 300 funded components. Dr. Shaw earned undergraduate degrees in Spanish and Biology at the College of William and Mary, and completed her doctoral degree in cell and developmental biology at Harvard University.
|Patrice Milos, PhD||Medley Genomics|
Co-founder/Presidente and CEO
Dr. Milos, a pioneer at the interface of genomics and medicine, currently serves as President and CEO of Medley Genomics - focusing company efforts on genomic analysis tools to decipher the complex genomic heterogeneity involved in many biological conditions. As a co-founder, Patrice has raised seed funding and obtained exclusive world-wide license with Brown University for a powerful suite of software solutions. Recently, Patrice was President/CEO at Claritas Genomics in Cambridge, MA. Claritas spun out of Boston Children's Hospital to realize the power of combining next-generation DNA sequencing with the clinical expertise of the world’s best pediatric specialists to inform patient care. Highlights included raising Series A/Series B funds, >$15M government contracts from the One Million Veteran Program, transitioning the lab to a world-class, CLIA/ISO-15189 laboratory, launching innovative molecular diagnostic products for pediatric rare disorders and implementing a rigorous approach to portfolio management. Previously, Patrice served as the Boston Site Head for Pfizer’s Centers of Therapeutic Innovation, establishing key Boston academic medical center partnerships. Dr. Milos also served as the SVP/CSO for Helicos BioSciences, Cambridge, MA and was Executive Director, Molecular Medicine for Pfizer Global Research and Development with responsibilities for genomic technologies and translational biomarkers applied across the Pfizer portfolio. Dr. Milos serves on the European Commission ULTRAPLACAD External Advisory Board, is an Advisor to Baby’s First Test and SeqLL. Patrice also serves on the BCH Technology Advisory Board, is an active NIH SBIR Grant Review Chair and has served on the National Advisory Council for NIH's Human Genome Research Institute. She sits on several journal editorial boards and has published extensively in genomic sciences. Dr. Milos conducted post-doctoral fellowships at Brown University and Harvard University and earned her MS and PhD degrees at Rensselaer Polytechnic Institute in Troy, NY.
|Oleg Moiseyenko||Bristol Myers Squibb|
Senior Cloud Architect, Scientific Computing Service
“The data is my jam and I think BIG data is better data! I also think compute clouds above the data lakes are more fun than real clouds & lakes!” Oleg Moiseyenko is Senior Cloud Architect for Scientific Computing Services at Bristol-Myers Squibb Company. He is Senior IT professional with 25+ years’ experience in cloud computing, big data, databases and high-performance computing (HPC) fields. Oleg holds multiple technical IT certifications in Amazon AWS cloud as well as in Oracle and Hadoop administration fields. With cloud technologies as his primary interests at Bristol-Myers Squibb Oleg supports scientific research operations in various systems used in discovery of new drug candidates (computational genomics). This includes researching, developing and implementing Big Data and cloud computing infrastructure / management standards across many AWS accounts using Big Data/HPC/Machine Learning technologies, relational/noSQL databases and requires advanced involvement in cloud computing services architecture, technical design and implementations including IaaS/PaaS/Saas delivery models. Oleg also supports numerous clusters with hundreds of CPU cores running in AWS cloud environment for Whole Genome, RNA-Seq, Proteomics and NGS workloads where various transformations and migrations of terabytes/petabytes scales data sets to clouds required. In his spare time, he enjoys outdoor activities combining this with film photography - using his trusty Deardorff and Rolleiflex cameras Oleg can be often found hiking all US National Parks capturing their beauty on film.
|Michael Montgomery, MD||Incyte Pharma|
former Global Head Medical Affairs
No bio available
|Jonathan Morris, MD||IQVIA|
Vice President, Provider Solutions; Chief Medical Informatics Officer, Real World Insights
No bio available
|Omesan Nair, PhD||EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany|
Design Analyst, Operational Design Center (ODC), Global Clinical Operations
The goal of the ODC is to enable improved study design through data-derived scenarios and optionality. The ODC is building an internal expert function that leverages big data and advanced analytics and applies consistent methodologies to achieve the optimal balance of time and cost in study design and execution. Omesan is a part of the ODC team with broad knowledge in Research and Development (R&D) and hands-on experience with data analytics and clinical research. He has been involved with various operations analyses and automation of analytics processes supporting R&D operations. His passion for clinical analytics stems from his work at the Red Cross Children‘s Hospital in Cape Town, South Africa where he conducted clinical data analysis on childhood brain cancers. Omesan has also been involved with analysis of translational research projects in this field and has collaborated with leading pediatric oncology centers at the Hospital for SickKids® in Toronto, Canada, and the German Cancer Research Center (DKFZ) in Heidelberg. He has also worked with investigations of immunological diseases using translational proteomics and gene expression data analysis. Omesan holds a PhD in Neuro-Oncology, MSc in Medical Biochemistry and BSc Honors in Molecular & Cell Biology from University of Cape Town, South Africa; with an Advanced Certificate in Bio-Entrepreneurship from University of Basel, Switzerland.
|Eric Neumann, PhD||AIDAKA LLC|
CEO & Founder
Dr Eric Neumann is CEO and founder of AIDAKA, a deep learning technologies and services company launched last June of 2017. AIDAKA leverages the solution finding power of deep learning systems together with existing prior biomedical knowledge, to solve many pharmaceutical and healthcare challenges. The unique system he has developed allows knowledge constructs to be injected into a deep learning network that the can process and train on biomedical data. His post-doctorate research with Dr. Jeffrey Hall (2017 recipient of the Nobel Prize in Medicine) on the genomic and phenotypic characterization of the gene Cacophony, was the first application of artificial neural networks in genomics.
Dr Neumann is a recognized world expert in semantic information and data modeling for the life sciences, and has worked on many information initiatives for the pharmaceutical and life sciences, including the W3C Semantic Web Healthcare and Life Sciences (HCLSIG), BioPAX, and OMG Life Sciences. Previously, Dr Neumann was Vice President of Knowledge Informatics at Foundation Medicine, responsible for organizing FMI’s knowledge assets and supporting knowledge discovery initiatives. Dr Neumann has co-founded several other companies, including Selventa, Clinical Semantics, Beyond Genomics, and PanGenx. He consults for pharmaceutical companies to enhance their management of scientific and pharmacological information. Dr Neumann is a graduate from MIT and holds a PhD in neurobiology, developmental genetics, and pharmacology from Case Western Reserve University.
|Todd Neuville||Amazon Web Svcs LLC|
Worldwide Lead - Life Sciences
Mr. Neuville joined AWS as the Worldwide Lead for Life Science, with over 30 years of experience in life sciences and technology. Prior to joining AWS he was Director of Customer Success at Salesforce, and Global Lead for Life Sciences in the Digital Transformation group at Cisco. He began his career at Merck, where he spent 25 years in positions of increasing responsibility, including Director of Commercial Operations, and Director of Customer Alliances and Innovation.
|Melissa Nisonger||NetImpact Strategies, Inc.|
Melissa Nisonger holds a Bachelor of Arts in Biology from Hood College in Frederick, Maryland. She has been an Analyst with NetImpact Strategies for over two years. During this time, she has been working alongside Dr. Ian Fore at the National Cancer Institute (NCI) to develop and execute a program for teaching and implementing collaboration skills at the Center for Biomedical Informatics and Information Technology (CBIIT). She has a passion for incorporating collaborative skills into all areas of science, and she recognizes the impact these skills have had on the organization as well as her own life as a wife and mother.
|Jean-Christophe Olivo-Marin, PhD||Institut Pasteur|
Head, BioImage Analysis Unit and Director, Institute Carnot Pasteur Microbes et Santé
Jean-Christophe Olivo-Marin is the Head of the BioImage Analysis unit and the director of the institute Carnot Pasteur Microbes et Santé. He chaired the Cell Biology and Infection Department (2010-2014) and was CTO and Director of the Center for Innovation and Technological Research (2015-2018). Previous to that, he was a staff scientist at the European Molecular Biology Laboratory, Heidelberg. He received the PhD and HDR degrees in optics and signal processing from the Institut d’Optique Théorique et Appliquée, University of Paris-Orsay, France. He is a Fellow of IEEE and of SPIE, an IEEE Signal Processing Society Distinguished Lecturer, and was Chair of the IEEE SPS Bio Imaging and Signal Processing Technical Committee (BISP-TC). His research interests are in image analysis of multidimensional microscopy images, computer vision and motion analysis for cellular dynamics, and in mathematical approaches for biological imaging.
|Larsson Omberg||Sage Bionetworks|
Vice President, Systems Biology
Dr. Omberg’s research effort focuses on two areas – using remote sensors and mobile phones to measure disease; and collaborative genomic research. Currently his group focuses heavily on open and team based science to get a large number of external partners to collaborate on data intensive problems. This includes establishing norms and methods for measuring disease phenotypes using remote sensors and developing analytical approaches for turning raw signals from sensors into digital biomarkers. Dr. Omberg and the Systems Biology group have been involved in over two dozen mobile health studies ranging from Chronic Anemia to Parkinson's Disease to cardio-respiratory fitness. As a graduate student and postdoctoral researcher at the University of Texas and Cornell University Dr. Omberg developed machine learning and statistical approaches for extracting genomic phenotypes and disease signals from system level biological data. After establishing a data science group at Sage Bionetworks his expertise was applied to coordinating data integration and integrative analysis for the TCGA Pancancer collaboration, The Progenitor Cell Biology Consortium as well as the international ICGC/TCGA Whole Genome Pan-Cancer Analysis among other projects. Dr. Omberg received a PhD in physics from the University of Texas at Austin.
|Gregory Pappas||U.S. Food and Drug Administration|
Associate Director, National Surveillance, Center for Biologics Evaluation and Research
No bio available
|Shez Partovi||Amazon Web Svcs LLC|
Director, Healthcare, Life Sciences, Genomics
Dr. Partovi obtained his MD from McGill University, and completed neuroradiology training at Barrow Neurological Institute. After a decade of clinical practice, he transitioned to serve as Chief Digital Officer for Dignity Health. Dr. Partovi joined AWS in 2018 as the Worldwide Director for Healthcare, Life Sciences and Genomics.
|Asaf Peer, PhD||Jackson Lab for Genomic Medicine|
Associate Computational Scientist
Throughout my graduate studies in computational biology my main focus was the evolution and mechanism of bacterial sRNAs. As sequencing technology matured my colleagues and I developed an experimental-computational method for detecting sRNA-mRNA interactions called RIL-seq, this procedure allowed us to capture the entire post-transcriptional regulatory network at any given time. I then entered the fascinating world of plant microbiome working for Evogene Ltd where I was involved in several projects. My main focus in JAX is next generation sequence analysis with a great emphasis on applying and developing tools for microbiome research. Education: The Hebrew University of Jerusalem, Israel PhD Computational Biology 2008-2014; The Hebrew University of Jerusalem, Israel BSc Computational Biology 2003-2006. Experience: Evogene Ltd, Computational Biologist/Computational Platform Development Leader, 2015-2018
|Dirk Petersen||Fred Hutchinson Cancer Research Ctr|
Scientific Computing Director
No bio available
|Thomas Plasterer, PhD||AstraZeneca|
Director of Bioinformatics, Data Science & AI, Biopharmaceutical R&D
Dr. Plasterer has pursued interests in bioinformatics, clinical informatics, systems biology and biomarker discovery over the last twenty years in both industry and academia. He co-founded PanGenX (a Personalized Medicine/Pharmacogenetics Knowledge Base start-up), directed the project planning and data interpretation group at BG Medicine, and held an adjunct professor position in the department of Chemistry and Chemical Biology at Northeastern University. He now leads FAIR data and Knowledge Graph initiatives at AstraZeneca. In these roles at AstraZeneca, Dr. Plasterer has been responsible for establishing and executing the linked data strategy which includes knowledge representation, vocabulary & metadata services, semantic visualization, analytics and business case development. This strategy has been deployed to build the competitive intelligence and integrative informatics frameworks for R&D. Tom also serves on the Pistoia Alliance FAIR data implementation board.
Founder and CSO
Corrado Priami is professor of computer science at the University of Pisa, director of the Pisa node of the Stanford SPARK Global initiative, and has 20+ years of academic and industrial experience in the application of computational technology for pharma and food companies. He is the founder of COSBI, that he led 12+ years as President and CEO. He managed projects for over euro 30 million (about euro 16 million for industrial projects). He served in the Senate of the University of Verona, in the BoD of the University of Trento, in the BoD of the Trento School of Management and in the BoD of COSBI as chairman of the board. He published over 200 scientific papers, gave more than 110 invited talks and lectures, regularly serves in advisory and scientific boards (including the Stanford SPARK program) as well as in reviewing panels for international funding agencies and institutions. He supervised more than 100 people (students, PhD students, Post-Docs) of which about 40 are now in senior or research positions in academia and industry. He got a master and PhD in computer science from the University of Pisa. He was post-doc with a competitive EU Marie Curie Grant at the Ecole Normale Superiéure in Paris (1996-97), researcher and associate professor at the University of Verona (1997-2001), visiting scholar at Microsoft Corp (2004), visiting professor at Stanford University (2016-17), professor at the University of Trento (2001-2017).
|Allison Proffitt||Bio-IT World|
Allison Proffitt is a science writer with a background in biology and chemistry, research experience in cancer biology, and an expanding repertoire in biotech, AI, and battery chemistry. She serves as the editorial director for the Healthtech Publishing media group, a growing collection of online news sites. In addition to Bio-IT World, her work has been published by Nature Biotech, Chemical & Engineering News, and the Economist Intelligence Unit. She has a bachelor’s degree in communication of science, engineering, and technology from Vanderbilt University and a Master’s degree in science and medical writing from Johns Hopkins University.
|Saiju Pyarajan, PhD||VA Boston Healthcare System|
Director, Center for Data and Computational Sciences; Faculty, Harvard Medical School
Saiju Pyarajan PhD Directs the Center for Data and Computational Sciences at the VA Boston Healthcare System. He also oversees the implementation and maintenance of the data and informatics infrastructure for the Million Veteran Program (MVP). Dr. Pyarajan completed his post-doctoral training from the Dana-Farber Cancer Institute and the NYU School of Medicine and obtained his PhD in Immunology from University of Massachusetts.
|John Quackenbush, PhD||Harvard T.H. Chan School of Public Health|
Henry Pickering Walcott Professor of Computational Biology and Bioinformatics; Chair, Department of Biostatistics
Dr. John Quakenbush is a professor of Computational Biology and Bioinformatics in the Biostatistics Department at the Harvard T.H. Chan School of Public Health and Dana-Farber Cancer Institute, as well as the director of the Center for Cancer Computational Biology (CCCB). His research group focuses on methods spanning the laboratory to the laptop that are designed to use genomic and computational approaches to reveal the underlying biology. In particular, they have been looking at patterns of gene expression in cancer with the goal of elucidating the networks and pathways that are fundamental in the development and progression of the disease.
|Srikanth Ramakrishnan||Janssen R&D|
Director, Intelligent Automation/Data Science
Srikanth is responsible for combining consulting and technologies expertise to transform the way IT is applied in Janssen’s R&D Intelligent Automation pursuits. His role as Business Technology Leader, is accountable for implementing technology initiatives in AI, Data Lakes and Robotic Process Automation. Srikanth partners with Janssen’s Global Medical Organization to provide technology leadership over ONESafety and PRISM programs, two of the largest transformational pharmacovigilance initiatives in the industry.
|Meghan Raman||Bristol Myers Squibb Co|
Head, R&D Data Lake and Analytics
Meghan Raman has 20+ years of experience in successfully leading large scale business transformation programs. She has cross industry domain expertise including Life Sciences, Financial, Consulting, Insurance, Telecomm and Resellers. She is experienced in building and leading global, high performance teams. She has also built Analytics frameworks and applications in multiple domains to drive revenue uplift and productivity. Meghan has led process development and implementation activities in Clinical, Regulatory and Pharmacovigilance domains. She has set up Analytics-as-a-Service framework and integration efforts between Product Registration, Safety Reporting and Clinical Trial Management. She is currently leading the R&D Data Lake and Integration portfolio for multiple domains including Translational Medicine, Clinical, Safety, Regulatory and Medical. Her current work enables data scientist access to clinical, operational, biomarker and real world data in a standard location, R&D Data Lake. Her work also enables scientist/clinicians capability to search biomedical terms. In addition her work provides data scientists a reproducible research environment with a business glossary, data catalog & lineage. Her other responsibilities include providing Study Start-up analytic capabilities and enabling a clinical metadata repository to store and manage clinical data standards.
|Vasu Rangadass, PhD||L7 Informatics|
|Brigitte Raumann||Globus, University of Chicago|
Product Manager, Digital Science
Brigitte Raumann earned her PhD in biology from MIT and was formerly Associate Director of Product Science at Incyte Genomics, Inc. After working for several years in educational multi-media, she has returned to field of genomics as Program Manager in the Initiative in Biomedical Informatics at the University of Chicago.
|Kamal Rawal, PhD|| |
Associate Professor, Amity University, India; Adjunct Faculty, Baylor College of Medicine, Houston, USA
Dr. Kamal Rawal is an interdisciplinary professional with extensive experience in machine learning and bioinformatics. He has successfully executed large scale complex projects such as Semi-Automated Text Mining System, AI based Vaccine Discovery System; Next Generation AI based Cancer Diagnostic System, & AI- Driven Obesity and Diabetes Management System. Currently, he is working as a Project Director in an International project. Concurrently, he hold a Associate Professor position in one of the leading university and mentoring several AI based startups.
Senior Director, Life Science Strategy
Jane is responsible for developing the strategic vision for Linguamatics; growing portfolio and business development. Jane has extensive experience in life science informatics. She worked for more than 15 years in vendor companies supplying data products, data integration and analysis, and consultancy to pharma and biotech.
|Kathy Reinold||Broad Institute of MIT and Harvard|
Principal Data Modeler
Kathy Reinold is a Principal Data Modeler at the Broad Institute of MIT and Harvard and holds Masters of Science degrees in both Computer Science and in BioInformatics. With roots in semantics and computer science and over 15 years experience with pharmaceutical and biotechnology challenges, Kathy builds data models connecting data in meaningful ways to enable researchers.
|Carlos Rios, PhD||Bristol Myers Squibb Co|
Senior Research Investigator, Computational Genomics – Translational Medicine
No bio available
|Emir Roach, MD||Takeda Pharmaceuticals|
Global Head, Emerging Technologies
Emir joined Takeda’s Enterprise Digital team in 2019 as the Head of Emerging Technologies and Data where he leads and oversees standing up and maturing strategic capabilities across Business Units/Therapeutic Areas. Prior to joining Takeda, Emir was a management consultant at McKinsey and Company focusing on life sciences strategy and digital transformation. His time at McKinsey was preceded by Cleveland Clinic where he completed his post-doctoral studies in translational clinical research, machine learning and initiated his post-graduate medical studies in internal medicine. He holds an MD from Hacettepe University.
|Kimberly Robasky, PhD||Renaissance Computing Institute (RENCI)|
Head, Translational Science
Dr. Robasky earned her PhD from Boston University on fellowship From George Church with Harvard’s Department of Genetics. She has 15+ years of experience in designing and delivering sustainable software systems, and spent several years as a scientist and product developer for a sequencing lab owned by Quintiles. Dr. Robasky joined the Renaissance Computing Institute (RENCI) in the fall of 2016 and holds adjuncts to both the Department of Genetics and the School of Information and Library Science at the University of North Carolina at Chapel Hill. Dr. Robasky has contributed to the NIH Biomedical Data Translator, NIH Data Commons Pilot, and the NIH Human Biomolecular Atlas Program. Dr. Robasky’s Translational Science team is currently working on applications in the areas of precision dosing, clinical trial management, and on solving problems in the modelling and analysis of clinical and biomolecular data.
|Alan Rogerson, BSc, MSc||Roche|
Principal Scientist, pRED Informatics – Early Development Informatics
Alan Rogerson's career at Roche has spanned over 20 years working in various global informatics teams. I’ve held positions as a project manager, service manager and applications specialist, working on a wide range of applications, platforms and projects mainly in the study management and clinical data management domains. My current role focuses on identifying and delivering solutions to improve and accelerate the delivery of early phase clinical trials.
|Jeffrey Rosenfeld, PhD|| |
Manager, Biomedical Informatics Shared Resource and Assistant Professor of Pathology and Laboratory Medicine, Rutgers Cancer Institute of New Jersey; President, Rosenfeld Consulting LLC
Dr. Jeffrey Rosenfeld has extensive experience in genomics and bioinformatics. He is the author of over 40 scientific publications, a graduate-level textbook, and the recipient of a US patent. He received his undergraduate education at the University of Pennsylvania and his PhD in biology from NYU. He performed his doctoral research at the prestigious Cold Spring Harbor Laboratory. Over his 15-year career in genomics, he has worked on a wide range of biological and genetic projects including genetic association studies of schizophrenia, genomic testing of embryos for fertility treatments, gene patent litigation, and clinical cancer genome sequencing. For the past five years, he has been an Assistant Professor of Pathology and Laboratory Medicine and the head of the Bioinformatics Core at the Rutgers Cancer Institute. In this role, he has become very familiar with laboratory testing both for cancer and other genetic diseases. He has set up the computational infrastructure for multiple tumor sequencing panels as well as a clinical data warehouse. Dr. Rosenfeld is always at the leading edge of technology and is looking for the newest ideas that can be used for scientific research and diagnostics including single cell techniques and long read sequencing. Additionally, Dr. Rosenfeld has been sought out for his expertise as the head of Rosenfeld Consulting LLC. Clients come to him seeking advice regarding genomics, oncology and laboratory testing. Due to his long tenure in the field and his knowledge of genomics as well as finance, he can give a clear assessment of the companies and their potential. Companies approach Dr. Rosenfeld looking for his expert-level genomics knowledge, industry insight and management experience.
|Philip Ross, PhD||Bristol Myers Squibb|
Director, Translational Bioinformatics Data Science
No bio available
Global Feasibility Therapeutic Area (TA) Head – Oncology
Gina Rothenberger is currently a Global Feasibility Therapeutic Area Head of Oncology for Janssen Research and Development LLC. Gina possesses a breadth and depth of experience at the site-level, CRO-level, and sponsor-level in providing feasibility, site identification and selection expertise. With over 15 years of industry experience, Gina focuses in the areas of business process optimization and quantitative and qualitative analysis to drive meaningful insights in shaping protocol design and the selection of the right country/six mix for clinical trials. Her recent work includes shaping a new data-driven end-to-end feasibility workflow and improved site identification approaches. Gina has a dual-degree in Biology and Psychology from Ursinus College.
Healthcare AI Principal
No bio available
|Terrell Russell, PhD||iRODS Consortium|
Terrell Russell is serving as the Chief Technologist of the iRODS Consortium at the Renaissance Computing Institute (RENCI). Terrell works on build and test for iRODS as well as code review, package management, documentation, and high-level architecture design. He's interested in distributed systems, metadata, security, and open source software that accelerates science. Terrell holds a BS in computer engineering, a BS in information technology and service organizations, an MS in computer networking from North Carolina State University, and a PhD in information science from the University of North Carolina at Chapel Hill. Terrell has been working on iRODS since 2008.
|Alok Saldanha, PhD||Novartis Institutes for BioMedical Research Inc|
Technical Associate Director
I am interested in systems biology, the immune system, sequence analysis and automation, omics methods such as single cell RNAseq and Somascan, digital devices for clinical trials and causal modeling of clinical and scientific data. At NIBR my group has developed web applications that track scientific workflows, automated data pipelines including external data sources and developed a shared services layer that has been used for three subsequent applications. We have been internalizing and scalably deploying open source software such as SPRING and cellxgene. AWS, Scala, Python and Typescript are some of my favorite tech.
|Ariella Sasson, PhD||Bristol Myers Squibb Co|
Senior Research Investigator
Ariella Sasson is a Senior Research investigator at Bristol-Myers Squibb. Ariella earned her undergraduate degree in mathematics and her doctorate in Computational Biology and Molecular Biophysics from Rutgers University. Quickly, her work began to focus around both technical and analytical aspects of Next Generation Sequencing. From her work in trying to identify genetic causes of pediatric diseases to working as part of the teams analyzing somatic data for the next biomarkers for treatment at BMS, she has played a leadership role in developing processing pipelines and storage solutions for genomic, transcriptomic, and proteomic from preclinical and clinical samples. Through her work, she has had the opportunity to work with large datasets allowing her to develop expertise in how to process, manipulate, and prepare data for analyses in a high throughput fashion.
|Sebastian Schlicker||Genedata, Basel, Switzerland|
Director, Biologics Business
Sebastian Schlicker has more than 15 years of experience in managing pharma R&D IT projects, specializing in the implementation of global enterprise software solutions for large molecule R&D. As the director of Genedata’s Biologics business, Sebastian oversees all major consulting and deployment projects globally. Currently based in Basel, Switzerland, Sebastian previously worked out of the Genedata Boston office, where he helped to build Genedata’s biopharma business in the US. Among his many responsibilities, he led implementation and customization projects for major US biopharma companies. Before joining Genedata, Sebastian worked at Sanofi, where he managed the implementation of new R&D platforms in both small- and large-molecule R&D, covering the complete project life-cycle and resulting in integrated and harmonized enterprise solutions used by scientists around the globe. Sebastian holds a degree in Computer Science and Economics from the University of Applied Sciences in Darmstadt, Germany.
|Lynn Schriml, PhD||Univ of Maryland Baltimore|
Associate Professor, Epidemiology and Public Health Department and Institute of Genome Sciences
Dr. Lynn M. Schriml is an Associate Professor at the University of Maryland, School of Medicine in the Department of Epidemiology and Public Health and at the Institute of Genome Science (IGS) in Baltimore, Maryland. Dr. Schriml’s current research focuses on developing bioinformatic tools, metadata standards and ontologies to gain a broader understanding of the relationship between infectious pathogens, their genomic sequence and disease. Dr. Schriml is a member of the Population Science Program within the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCC) Program in Oncology. Population Science researchers collaborate with investigators throughout the University of Maryland System to identify determinants of cancer etiology and survivorship, characterize cancer-related health behaviors, and translate basic discoveries into behavioral cancer prevention and control interventions. Dr. Schriml’s research centers on developing and implementing ontological tools aimed at classifying and unifying cancer nomenclature and term usage. Dr. Schriml leads a number of ontology and metadata standard development and implementation projects. As PI of the Alfred P. Sloan Foundation funded Built Environment MIxS-BE Metadata project. Dr. Schriml leads efforts to provide tools to foster standard metadata collection and analysis across the Microbiology of the Built Environment program. As PI of the Disease Ontology, Dr. Schriml leads ontology community-based curation, expansion and utilization efforts. The Human Disease Ontology, a broadly adopted standard, is utilized across biomedical databases and resources for knowledge and data sharing through standardized annotation of biomedical data. Dr. Schriml’s group is currently focused on the classification and annotation of rare diseases and cancer, actively engaged with the Model Organism Databases to standardize human diseases associated with animal models.
Dr. Schriml’s work involves extensive collaborative interactions with a diverse community of researchers and development of research projects involving consortiums, government and private sector collaborators. As a project leader, board member (President) and developer in the Genomic Standards Consortium (GSC), Dr. Schriml is a promoter of metadata standards development and integration for genomic projects, including the HMP-DACC and NIAID GSCID projects hosted at the Institute for Genome Sciences, University of Maryland, Baltimore, into large scale genome databases (e.g. NCBI’s BioSample, NIAID BRC’s, JGI’s GOLD database). Dr. Schriml is the primary developer of a suite of OBO Foundry biomedical ontologies including the Disease Ontology, Symptom Ontology, Transmission Method Ontology, Influenza Ontology, Environmental (EnvO) ontology and geographic locations gazetteer (GAZ) vocabulary. Following Dr. Schriml’s postdoctoral research at the National Cancer Institute - Frederick Cancer Research and Development Center conducting population studies and characterizing mouse ABC-transporters, Dr. Schriml transitioned to bioinformatics. Dr. Schriml development bioinformatics tools for model organism genome projects at the National Center for Biotechnology Information (NCBI) at NIH as a Staff Scientist prior to joining the Institute for Genome Research (TIGR) in 2005 to develop the microbial surveillance Gemina project.
|Ajay Shah, PhD, MBA||Bristol-Myers Squibb|
Executive Director & Head of IT for Translational Medicine
Ajay Shah is Executive Director and Head of Translational Medicine IT at BMS, where he is responsible for platforms and solutions ranging from semantic integration of R&D data, biomarker characterization, precision medicine, imaging, bioinformatics, bio-analytical sciences, and laboratories, etc. Prior to BMS he headed Research Informatics (Discovery, Clinical and Translational) and Research IT at City of Hope National Medical Center. He has held roles of Director of Research Informatics at Elan Pharmaceuticals and Associate Director of Cheminformatics at Pfizer after starting his career at Biosym (now Biovia) in scientific software development and scientific support roles.
|Heather Shapiro, PhD||Pear Therapeutics|
Head of Data Science
No bio available
|Vishakha Sharma, PhD||Roche Molecular Systems Inc|
Principal Data Scientist
Vishakha Sharma is a Principal Data Scientist for diagnostic information solutions at Roche, where she leads advanced analytics initiatives such as natural language processing (NLP) and machine learning (ML) to discover key insights improving NAVIFY product portfolio, leading to better and more efficient patient care. Vishakha has authored 40+ peer-reviewed publications and proceedings and has given 15+ invited talks. She serves on the program committee of the ACM-W, NIPS, AMIA, and ACM-BCB. Her research work has been funded by the NIH Big Data to Knowledge (BD2K) initiative to build an NLP precision medicine software to automate molecular and clinical information extraction, categorization, and ranking of clinical evidence associated with biomarkers that predict response to cancer therapies. She holds a PhD in computer science.
|Alex Sherman||Massachusetts General Hospital|
Director, Center for Innovation and Bioinformatics
Alex has 30+ years of experience in research, software development, software architecture, expert systems design, clinical trials systems design, data management and clinical trials management. As the Director of Systems at the Neurological Clinical Research Institute (NCRI), Mr. Sherman is responsible for the successful design, development and deployment of software systems for numerous clinical trials and biomarker studies in ALS, Huntington’s disease, Parkinson’s disease, stroke and depression. Alex conceived and was instrumental in design, development and adoption by the international research community of NeuroBANK™, an accelerated clinical research platform, and ALSBANK™ platform, a virtual distributed biorepository currently utilized by numerous researchers and institutions. His team was responsible for design and implementation of PRO-ACT project that created the largest clinical dataset in ALS (10,700+ subjects) and is the de-facto reference dataset in ALS research. This platform was selected as the Best Bio-IT project of 2013 by the Bio-IT World Congress. Alex served on the NINDS Common Data Elements committee, is the Chair of the NeuroBANK™ committee of NEALS.
|Gaurav Singal, MD||Foundation Medicine Inc|
Chief Data Officer
Gaurav Singal, MD, was named Chief Data Officer of Foundation Medicine in February, 2019. Since joining the company in 2013, Dr. Singal and his team have architected and launched technology and data-centric products that have accelerated patient access to therapy and positioned Foundation Medicine as a leader in molecular information in cancer care. Dr. Singal is a physician and computer scientist who initially joined Foundation Medicine to lead an innovation unit focused on new software and data products. To accelerate the vision of bringing real world data to point of care providers, Dr. Singal and his team developed collaborative relationships with clinical data companies, including Flatiron Health. Under Dr. Singal’s leadership, these partnerships have led to the development of the Foundation Medicine-Flatiron Clinico-genomic Database (CGDB), a best-in-class dataset linking genomic information to real-world clinical data which is helping advance personalized healthcare with both biopharma and clinical partners. In addition, Dr. Singal and his team have developed and launched FoundationInsights™, our cloud-based platform for genomic data analysis and visualization, and SmartTrials™, a program that leverages our dataset to help patients access molecularly targeted medicines through clinical trials. These platforms and services have delivered unparalleled value by enabling our partners to accelerate the delivery of novel, personalized therapies to patients. Prior to Foundation Medicine, Dr. Singal led the development of several natural-language processing (NLP)-based applications to improve efficiency in healthcare delivery and research at Massachusetts General Hospital. His NLP research platform, SoothSayer, has been the basis for several scientific presentations and publications. He received his BS, summa cum laude, in computer engineering with a focus on AI and machine learning from Columbia University, earned an MD with honors from the Harvard-MIT division of Health Sciences and Technology, and completed residency training in Internal Medicine at Massachusetts General Hospital. He continues to see patients as an attending physician at Brigham and Women’s Hospital in Boston, and co-directs a graduate course on health technology and innovation as a member the Harvard Medical School faculty.
|Shantanu Singh, PhD||Broad Institute of MIT and Harvard|
Senior Group Leader, Imaging Platform
Shantanu Singh is a senior group leader in the Imaging Platform at the Broad Institute. He leads a data science group that develops computational and statistical methods to create fingerprints of genes, chemicals, and diseases from microscopy images of cells. Using assays like Cell Painting that capture a broad range of their morphological properties, cellular populations are characterized at single-cell resolution to discover similarities and differences among treatments. This work has the potential to transform how both the targets and therapies for disease are identified. After completing his PhD at Ohio State in computer science, Shantanu joined the Imaging Platform, inspired by the group’s vision to make cell morphology as computable as genomes. He has previously worked in research groups at Mercedes-Benz R&D, GE Global Research, and Lawrence Livermore National Laboratory, where he applied computer vision and machine learning techniques to a wide range of problems in road safety, cell biology, and geospatial imaging.
|Tim Skelton, MD, PhD||Lahey Hospital & Medical Center|
Medical Director, Core Laboratory & Laboratory Informatics
Dr. Skelton is Board Certified in Clinical Pathology and Clinical Informatics, received a BS degree from MIT, and MD/PhD degrees from Washington University in St. Louis. Residency & Fellowship training were completed at Massachusetts General Hospital. Dr. Skelton is a leader in the implementation of new approaches to the clinical practice of Laboratory Medicine that impact the economics and outcomes of patient care. He has combined research, industry collaboration, and informatics toward the development of innovative lab-based algorithms that maximize an integrated healthcare system’s ability to deliver high-quality low-cost patient care. Areas of expertise include Hematology, Coagulation, Cancer Biomarkers, Endocrinology, Critical Care, Urinalysis, and Chemistry. Dr. Skelton teaches a graduate course on Clinical Laboratory Quality in the Clinical Laboratory Sciences Department at University of Massachusetts Lowell.
|Christopher Southan, PhD||TW2Informatics|
Dr Christopher Southan, works at the interface between bioinformatics, cheminformatics, pharmacology and drug discovery. His current role as Principle Consultant at TW2 informatics in Göteborg, Sweden was preceded by Senior Cheminformatian for the Edinburgh University BPS/IUPHAR Guide to Pharmacology database team 2013-18. Prior to this he set up TW2Informatics, engaging in patent data consulting for SureChem (2011-12) and the AstraZeneca Knowledge Engineering Program for testing and documenting Chemistry Connect (2009-11). During 2008-9, he coordinated the ELIXIR Database Provider Survey at the EBI, preceded by a Principle Scientist and Bioinformatics Team Leader position in AstraZeneca, Mölndal (2004-7) preceded by senior bioinformatics positions at Oxford Glycosciences Gemini Genomics and SmithKline Beecham. He has a PhD in Protein Chemistry from the Ludwig Maximillian University of Munich and a BSc Hons in Biochemistry from Dundee University (further information on LinkedIN).
|Ola Spjuth, PhD||Uppsala University|
Associate Professor, Department of Pharmaceutical Biosciences
Ola Spjuth is Associate Professor at the Department of Pharmaceutical Biosciences leading a research group on Intelligent systems for drug discovery and chemical safety. Research activities are focused on how automated high-throughput and high-content molecular and cell profiling technologies coupled with AI and predictive modeling on modern e-infrastructures can enable us to study complex phenomena in pharmacology, toxicology and metabolism. Research group website: https://pharmb.io/
|Andreas Steinbacher, PhD||Roche Innovation Center Munich|
R&D Informatics and Machine Learning/Artificial Intelligence Leader for Lab Automation
No bio available
|Ludovic Sternberger, PhD||F Hoffmann La Roche AG|
Principal Scientist, pRED Informatices
Successful software engineer and architect with substantial scientific development experience. Holds a PhD in Computer Science in the field of Virtual Reality, 2D/3D GUI and Human Computer Interaction. Enjoys equally working at all aspects of product development, from architecture to implementation. 10 years’ experience writing, designing, architecting and delivering scientific and mission-critical software. Especially interested in solving issues and empowering customers, applying agile software engineering methodologies. He is also a strong advocate of agile software development, clean code and software craftsmanship (Uncle Bob, Martin Fowler, Kent Beck, etc.) and test-driven software development.
|Etzard Stolte, PhD||F. Hoffmann-La Roche|
Global Head, Knowledge Management PTD,
Etzard leads the global Information/Knowledge Management effort in Pharma Technical Development for F. Hoffmann-La Roche in Basel, with a focus on processes and tools for effective knowledge utilisation. Etzard has worked at the interface of the Life- and Computer-Sciences for more than 20 years, in technical, managerial as well as strategic roles. Before joining Roche, Etzard worked as CIO at the Jackson Lab (a US based genomics research institutes), and was CTO for the Life Sciences at Hewlett Packard (a large technology vendor). Etzard has earned academic degrees in Biology, Bio-Informatics and Informatics, with a PhD in Computer Science from ETH Zurich on "A Scalable Architecture for Scientific Databases”.
Head Developer, Drug Design, Hub Development
No bio available
|Iman Tavassoly, MD, PhD||Icahn School of Medicine at Mount Sinai|
Physician-Scientist, Mount Sinai Institute for Systems Biomedicine
Iman Tavassoly MD, PhD is an Assistant Professor of Systems Biology in Mount Sinai Institute for Systems Biomedicine of Icahn School of Medicine at Mount Sinai. He works in the field of cancer systems biology and precision oncology.
|Deanne Taylor, PhD||Children's Hospital of Philadelphia|
Director of Bioinformatics, DBH
Deanne Taylor joined DBHI in 2014 as the Bioinformatics Director. Deanne oversees the design, development, and implementation of high performance innovative bioinformatics workflows and provide technical leadership and supervision of a multidisciplinary bioinformatics team at CHOP. Previously, she was Director of Bioinformatics with Reproductive Medicine Associates and Assistant Professor with the Department of Obstetrics, Gynecology and Reproductive Medicine at Rutgers Robert Wood Johnson Medical School. Prior to that she worked for Harvard School of Public Health as a Research Scientist and served several years as the Program Director of the Graduate Program in Bioinformatics at Brandeis University. She also has experience working in the pharmaceutical industry. Deanne obtained her PhD in Biophysics from the University of Michigan, Ann Arbor, and completed a postdoctoral fellowship at Pfizer. Her background is in biophysics, bioinformatics, computational biology and structural biology with emphasis on human genetics and translational medicine. Deanne's main areas of research are in the development of mathematical and computational methods to better understand biological variation and the genetic contribution to disease, coupling clinical information with high-dimensional biomedical data from next-gen sequencing, microarray, PCR, and proteomics experiments.
|Jason Tetrault||Takeda Pharmaceuticals Inc|
Global Head Data Engineering and Emerging Technologies
No bio available
Head, Clinical & Biomarker Informatics
No bio available
|Matthew Trunnell||Fred Hutchinson Cancer Research Ctr|
Vice President and Chief Data Officer
In his role at the Fred Hutchinson Cancer Research Center, Matthew Trunnell oversees enterprise and scientific computing services and leads the Hutch Data Commonwealth, a team of data analysts and software engineers building new capabilities to leverage clinical data for research. Trunnell is also working to forge connections between the Hutch and the broader technology community in the Pacific Northwest to help power cancer research. Trunnell came to the Hutch from the Broad Institute of MIT and Harvard, where he had served as head of CIO and manager of research computing, during the period of explosive growth in research data infrastructure capabilities, in support of the growth in next-generation sequencing activities. As IT and informatics became more central to the large-scale generation of data, Trunnell initiated a new organization within the Institute, bringing together computational biologists and professional software engineers focused on developing advanced informatics capabilities. Having starting his professional life as a computational oceanographer, Trunnell found his way into the genomics world in the late 90’s and has been supporting applied scientific computing in both academic and commercial environments since.
|George Vacek||NVIDIA Corp|
Director, Scientific Instrumentation & Medical Devices
No bio available
|Kees Van Bochove||The Hyve|
Kees studied Computer Science and Bioinformatics, for which he did his research project on lipoprotein metabolism at TNO Quality of Life in The Netherlands and the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston. Through his many years of experience in open source software and standards development in bioinformatics, Kees has gained a deep understanding of all aspects of collaborative open source development. He founded The Hyve to facilitate open source software development in bioinformatics and clinical research.
|Geraldine Van der Auwera, PhD||Broad Institute of MIT and Harvard|
Director of Outreach and Communications
Geraldine Van der Auwera directs outreach and communication efforts to the global scientific research community on behalf of the Data Sciences and Data Engineering (DSDE) group at the Broad Institute. Her team's efforts include technical support, documentation, social media presence and user education events for users of software produced in DSDE. This includes GATK, the Broad's industry-leading toolkit for variant discovery analysis; Cromwell/WDL, an increasingly popular open-source pipelining solution; and FireCloud/Workbench, a cloud-based analysis platform that integrates computational resources, methods repository and data management in a user-friendly environment. Prior to joining the Broad Institute, Van der Auwera was a post-doctoral fellow in the Kolter lab at Harvard Medical School, researching the genomic structure of the bacterial family Bacillus cereus sensu lato from the point of view of ecotypical differentiation and interspecies interactions. She received her PhD in Biological Engineering from the Université catholique de Louvain (UCL) in Louvain-la-Neuve, Belgium in 2007. As an undergraduate, Van der Auwera studied Biological Sciences with a concentration in Microbiology and Genetics, also at UCL in Belgium.
|William Van Etten, PhD||BioTeam Inc|
Senior Scientific Consultant & Founding Partner
As a PhD geneticist, Van Etten contributes the perspective of a scientist in helping clients solve their computer-aided research problems. Van Etten honed his informatics skills at the Whitehead Institute Center for Genome Research at MIT before co-founding BioTeam in 2002. Since then he has specialized in the development of informatics software with a keen eye toward ease of use. Van Etten received his Doctorate of Philosophy in Genetics at Indiana University in Bloomington, Indiana. Following his graduate research Bill was Senior Software Engineer at the Whitehead Institute Center for Genome Research where he contributed to the genetic mapping of the rat, and was the Head of Informatics for the Mouse Radiation Hybrid Mapping Project as well as Whitehead’s contribution to the SNP Consortium. Bill was involved with the generation of 2 million DNA sequences, and the discovery of 1.4 million Human SNPs; having developed and optimized novel algorithms for SNP discovery. He took these high-throughput computing research skills to Blackstone Computing as Principal Bioinformaticist where he designed, built and configured environments to support computer-aided research for life sciences.
|John Van Hemert, PhD|| |
Research Scientist, Bioinformatics, Corteva Agri Science, A Dow-Dupont Division
Formally trained in Computational Biology, Multivariate Statistics, and Machine Learning, John worked in Discovery R&D at DuPont Pioneer since 2011. Projects are balanced between developing computational methods that enrich the discovery pipeline and characterize its products – some of which appear in scientific and IP literature. He led statisticians, computational biologists, and data scientists around the world, working on everything from experiment design, to drone imagery analysis, to molecular biotechnology development. Before that, he was a Staff Scientist at Iowa State University in the Crop Genome Informatics Laboratory where he led modernization of the Plant Expression DataBase (PlExDB). Prior, John received his PhD (2010) from the Electrical and Computer Engineering Department at Iowa State University in Bioinformatics and Computational Biology, where he worked on Systems Biology of the Grapevine for an international consortium of researchers and published several papers in biological network analysis and mining. He also holds Bachelors’ degrees (2006) from the University of Northern Iowa, by the Computer Science Department and Business College.
|Dana Vanderwall, PhD||Bristol Myers Squibb|
Director, Biology & Preclinical Sciences IT, Research & Development IT
Dana Vanderwall is Director of Biology & Pre-Clinical IT at Bristol-Myers Squibb and is responsible for the strategy to enable data flow, analytics, knowledge capture, and provide general laboratory informatics capabilities to the Biology, Pharmaceutical Candidate Optimization, Drug Safety Evaluation and Veterinary Sciences functions at BMS. He is Chair of the Allotrope Foundation Board of the Directors, contributes projects within the Pistoia Alliance and is Fellow of the Society for Lab Automation and Screening. Prior to joining BMS Dana was at GlaxoSmthKline and Merck, and integrates experience from work in Computational Chemistry, Cheminformatics, Computational & Structural Biology, and Biochemistry. He received his BS in Biochemistry at the University of Wisconsin, and his PhD in Biochemistry at University of Maryland.
|Vas Vasiliadis||Globus, University of Chicago|
Chief Customer Officer
Vas is Chief Customer Officer for Globus, an innovative software-as-a-service for research data management, developed and operated by the University of Chicago. His responsibilities include sales, marketing, customer support, training, and generally working with current and prospective users to grow adoption of the service and make it self-sustaining. Vas is also a lecturer in the Masters Program in Computer Science, where he teaches courses on Cloud Computing and Product Management. Vas has 30 years of experience in operational and consulting roles, spanning strategy, marketing and technology. An experienced software product marketing professional with a passion for shaping emerging technologies to bring innovative products to market, Vas has nurtured early stage companies into successful businesses, and consulted to companies on a wide range of strategic issues. Prior to joining the University, Vas was a principal at Strategos, the innovation consulting firm founded by Gary Hamel, where he led Fortune 100 management teams in defining their growth agenda. Earlier, Vas led marketing efforts at Univa, a leading provider of grid and cloud computing solutions. Vas joined Univa's founding team shortly after inception and was instrumental in defining the product vision, raising venture capital and launching the company's initial products. In the late 1990's Vas served as vice president of product management and corporate strategy at CrossWorlds Software, the enterprise application integration pioneer, and was part of the executive team that grew CrossWorlds from a start-up to a successful public company that was subsequently acquired by IBM. Vas was also chief technology officer at Cimnet Systems, a company specializing in software for electronics manufacturing, which was acquired by Consona in 2005. At Cimnet he led product strategy and development of the company's supplier management and business intelligence solutions. Prior to Cimnet, Vas was vice president of strategy and product management at Promeria, a supplier relationship management company which was acquired by Ariba. Vas' management consulting experience includes Booz & Company (now Strategy&), where he focused on supply chain strategy and customer service level optimization, and Accenture, where he helped clients in the financial services industry automate trading and back office operations. He has a deep technical understanding of system development for real-time applications, including data distibution, analytics, and trading platforms for derivatives and fixed income securities. Vas holds an MBA with High Distinction from the Ross School of Business at the University of Michigan, Ann Arbor and a BS in Electrical Engineering from the University of the Witwatersrand in South Africa. He remains a network partner with Strategos and is an advisor to early-stage technology companies on all aspects of strategy, marketing, and product management.
|Jérôme Waldispühl, PhD||McGill University|
Associate Professor, School of Computer Science
I conduct research in computational molecular biology with a particular interest on RNA structural bioinformatics and cheminformatics. I also develop applications of crowdsourcing and human-computing techniques to bioinformatics, a field of research I contributed to pionneer with the citizen science video game Phylo DNA Puzzles. I received a PhD in Computer Science from École Polytechnnique (France) in 2004 under the mentorship of Jean-Marc Steyaert. From 2005 to 2006, I was a post-doctoral researcher in the group of Peter Clote at Boston College, and in 2006 I moved to the Massachusetts Institute of Technology where I was an instructor in applied mathematics under the mentorship of Bonnie Berger. In 2009, I joined the School of Computer Science at McGill University as faculty member. I am a recipient of the Tomlinson Scientist Award in 2012, and the Fessenden Professorship in Science Innovation in 2013. You can learn more about my research on my laboratory website. If you want to join the lab, you can find more information about how to apply for a position in my group on my research website. We do currently have several open PhD student positions.
|Albert Wang, MS||Bristol-Myers Squibb|
Director, IT for Translational Research & Technologies
Albert Wang is the Director of IT for Translational Research & Technologies at Bristol-Myers Squibb. He has nearly 20 years of experience in designing and building technologies for accelerating all phases of drug research & development, from early target identification to biomarker discovery to post-launch medical research. Currently, his focus is on executing an enterprise-wide digital health data strategy for integrating patient-centric data across BMS, including clinical trial data, molecular data, and real-world evidence. He has a Bachelor's degree n Biomedical Engineering and a Masters degree in Bioinformatics from the University of Pennsylvania.
|Ethan Yaoyu Wang, PhD||Harvard T.H. Chan School of Public Health|
Senior Research Scientist, Department of Biostatistics
No bio available
|Monica Wang, PhD||Takeda|
Principal Technology Lead, Scientific Informatics
Monica currently leads the Biology (including Biologics) Capabilities and Products in Takeda Scientific Informatics. She comes with multidiscipline education with PhD in Biochemistry and MSc in Software Engineering. She has 8+ years of experience in academic research and 15+ years of experience in Research Informatics in the biotechnology and pharmaceutical industries. She is good at strategic planning with proven successful track records of managing complicated global enterprise informatics projects. She has delivered many informatics projects/programs within time and budget for many departments (Global Biologics, Molecular Pathology, Protein Science, Biotherapeutics, Translational Medicine and Legal IP, et al). She is technically and scientifically proficient in Bioinformatics, Cheminformatics, Functional Genomics, and Pharmacogenomics. Her team has designed and implemented many global enterprise informatics solutions to support biologics research, biomarker discovery, translational research and personalized medicine. Her recent focus is concentrated on building a state-of-art Global Biologics Platform to support the global biologics R&D research in Oncology, GI and CNS across Takeda.
|Michael Waters, PhD||U.S. Food and Drug Administration|
Team Lead, System Harmonization and Interoperability Enhancement for Laboratory Data
Dr. Waters is the team lead for the multi-agency/stakeholder Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD) effort and the Real-World Evidence representative for the Office of In Vitro Diagnostics and Radiological Health (OIR) at FDA. He is an interdisciplinary scientific reviewer for a wide range of medical devices, with a focus on diagnostics, instrumentation and software. He leads efforts to build laboratory data infrastructure for a National Evaluation System for healthcare Technology (NEST) under the Medical Device Innovation Consortium (MDIC). Dr. Waters also participates in several data interoperability working groups, to implement infrastructure and improve lab data interoperability. Dr. Waters received his PhD from the USC Department of Molecular and Computational Biology, conducted his postdoctoral research at the National Institute of Standards and Technology (NIST) and was a Research Fellow for the National Research Council (NRC). He has over 20 years of experience in microbiology and molecular biology.
|Paul Whitehead, PhD||Bristol Myers Squibb Co|
Head, IT Business Partner, Leads Discovery & Optimization
No bio available
|ClarLynda Williams-DeVane, PhD||Fisk Univ|
Chair, Data Science and Bioinformatics
No bio available
|Elizabeth Worthey, PhD||Univ of Alabama Birmingham, Birmingham School of Medicine|
Director, Genomic Medicine
Elizabeth “Liz” Worthey, PhD joined the Department of Pediatrics in the Division of Pediatric Hematology/Oncology as the director for the Center for Genomic Data Sciences in the Departments of Pediatrics and Pathology in the School of Medicine in June 2019. As part of her secondary appointment in the Department of Pathology, Dr. Worthey will serve as the director of the Bioinformatics Section in the Division of Genomics Diagnostics and Bioinformatics. She will also serve as the associate director for the Hugh Kaul Precision Medicine Institute. She is currently a faculty investigator and director of Software Development and Informatics at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. Prior to her position at HudsonAlpha, Dr. Worthey served as an assistant professor in pediatrics and the director of Genomic Informatics for the Human and Molecular Genetics Center at the Medical College of Wisconsin in Milwaukee, Wisconsin. Dr. Worthey received her PhD at the Imperial College London in London, England and completed her postdoctoral training at the Seattle Biomedical Research Institute and the University of Washington in Seattle, Washington. Her research interests include the development and application of omic, informatic, and data science based methods and technologies in order to identify and understand causal molecular variation in rare, undiagnosed or misdiagnosed disease. Her lab also focuses on the identification and study of variation that alters an individual's response to therapeutics or modifies clinical presentation, progression, and/or outcome.
|Grace Wenjia You, PhD||EMD Serono|
Director, Head, Global Portfolio Management, Valuation & Analytics
Grace You is currently leading Global Portfolio Valuation and Analytics for the Healthcare Sector of Merck KGaA, Darmstadt, Germany. Prior to that, Grace led key strategy and analytics projects at MilliporeSigma, the Life Science Sector of Merck KGaA and a premier Life Science company. Previously, Grace was a management consultant at the Boston Consulting Group, working with a range of global pharmaceutical companies across their top priority strategy and implementation projects. Grace holds a PhD in Neurobiology from Harvard University, and a BS in Chemistry & Biology from Tsinghua University.
|Lauren Young||Beam Therapeutics|
Senior Scientist, Computational Biology
No bio available
|Lijian Yu, PhD||AbbVie|
Senior Bioinformatics Specialist
No bio available
|Baohong Zhang, PhD||Biogen|
Director of Genome Informatics
Over 15 years of R&D experience in biotechnology and pharmaceutical companies on computational biology, systems biology and precision medicine. Has been focused on developing automated data processing pipelines for next generation sequencing (NGS) data to speed up processing, visualizing and data mining in genome scale involving billions of data points.
|Alex Zhavoronkov, PhD||Insilico Medicine Hong Kong|
Founder and CEO
Dr. Alex Zhavoronkov is the founder and CEO of InSilico Medicine, a global leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At InSilico, he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties and generation of synthetic biological and patient data. His group was the first to develop the deep-learned multi-modal predictors of age for drug discovery and biomarker development. He set up the R&D centers in 6 countries, including the United Kingdom, Korea, Russia, Hong Kong SAR, and Taiwan ROC. Prior to founding InSilico Medicine, Dr. Zhavoronkov worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, and YLabs.AI and established the AgeNet.net competitions and Diversity.AI initiatives. He is co-founder and CSO of the Biogerontology Research Foundation (BGRF), a registered UK charity focusing on age-related diseases. Since 2012, Dr. Zhavoronkov published over 120 peer-reviewed research papers and 2 books, including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). From 2014 to 2018, he presented at over 200 academic and industry conferences. Dr. Zhavoronkov serves on the editorial boards of some of the highest-impact journals in the field, including Aging, Aging Research Reviews, Frontiers in Genetics of Aging, Trends in Molecular Medicine, and chairs the Annual Aging Research for Drug Discovery Forum (6th annual in 2019) at the Basel Life. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
|Kelly Zou, PhD, PStat®, ASA Fellow||Pfizer, Inc.|
Vice President, Head of Medical Analytics and Insights Research, Development and Medical, Upjohn Division
Kelly Zou, Ph.D., FASA, PStat® is Vice President, Medical Analytics & Insights, R&D and Medical, Upjohn Division, Pfizer Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously, she was Senior Director, Global Real World Evidence Center of Excellence and Senior Director, Statistical Center for Outcomes, Real World & Aggregate Data at Pfizer. She was Associate Professor at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals. She was Associate Director of Rates at Barclays Capital. She received both MA and PhD degrees in Statistics from the University of Rochester, following a BA in Mathematics (Summa Cum Laude), with a Minor in Physics. She completed her Postdoctoral Fellowship at Harvard. Her research interests include health policy, real world evidence, signal detection, and artificial intelligence, with over 140 professional articles and 4 books. She was featured as an Outstanding Woman in Data Analytics by Forbes, an Inspirational Women in Statistics & Data Science by Wiley and the Royal Statistical Society, and an Accomplished Woman in Statistics and Data Science by the ASA.